0001144204-16-133783.txt : 20161114 0001144204-16-133783.hdr.sgml : 20161111 20161114100115 ACCESSION NUMBER: 0001144204-16-133783 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 44 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161114 DATE AS OF CHANGE: 20161114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASI Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0000895051 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581959440 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-20713 FILM NUMBER: 161991521 BUSINESS ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-864-2600 MAIL ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ENTREMED INC DATE OF NAME CHANGE: 19960415 10-Q 1 v452325_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to _____________.

Commission file number 0-20713

CASI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		58-1959440
(State or other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)

9620 Medical Center Drive, Suite 300

Rockville, Maryland

(Address of principal executive offices)

20850

(Zip code)

(240) 864-2600

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES x NO ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES x NO ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer ¨

Smaller reporting company x

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ¨ NO x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most recent practicable date.

Class		Outstanding at November 7, 2016
Common Stock $.01 Par Value		60,196,574

CASI PHARMACEUTICALS, INC.

Table of Contents

		PAGE
PART I. FINANCIAL INFORMATION		4

Item 1 — Consolidated Financial Statements		4

Condensed Consolidated Balance Sheets as of September 30, 2016 (unaudited) and December 31, 2015		4

Condensed Consolidated Statements of Operations for the Three Months and Nine Months Ended September 30, 2016 and 2015 (unaudited)		5

Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and 2015 (unaudited)		6

Notes to Condensed Consolidated Financial Statements (unaudited)		7

Item 2 —	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3 —	Quantitative and Qualitative Disclosures About Market Risk	23

Item 4 —	Controls and Procedures	23

Part II. OTHER INFORMATION		24

Item 1 —	Legal Proceedings	24

Item 1A —	Risk Factors	24

Item 2 —	Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3 —	Defaults Upon Senior Securities	24

Item 4 —	Removed and Reserved	24

Item 5 —	Other Information	24

Item 6 —	Exhibits	24

SIGNATURES		25

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements also may be included in other statements that we make. All statements that are not descriptions of historical facts are forward-looking statements. These statements can generally be identified by the use of forward-looking terminology such as “believes,” “expects,” “intends,” “may,” “will,” “should,” or “anticipates” or similar terminology. These forward-looking statements include, among others, statements regarding the timing of our clinical trials, our cash position and future expenses, and our future revenues.

Our forward-looking statements are based on information available to us today, and we will not update these statements.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances, including as a result of the closing of the private placement offering; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission (“SEC”), which are available at www.sec.gov.

PART I. FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

CASI Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

	September 30, 2016			December 31, 2015
	(Unaudited)			(Note 1)
ASSETS
Current assets:
Cash and cash equivalents	$	24,137,329		$	5,131,114
Prepaid expenses and other		401,080			438,231
Total current assets		24,538,409			5,569,345

Property and equipment, net		184,090			218,796
Other assets		34,485			38,174
Total assets	$	24,756,984		$	5,826,315

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	918,892		$	884,100
Accrued liabilities		161,978			169,464
Note payable, net of discount		1,485,985			-
Total current liabilities		2,566,855			1,053,564

Note payable, net of discount		-			1,464,970
Contingent rights derivative liability		6,167,142			9,395,222
Total liabilities		8,733,997			11,913,756

Commitments and contingencies

Stockholders’ equity (deficit):
Convertible preferred stock, $1.00 par value; 5,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2016 and December 31, 2015		-			-
Common stock, $.01 par value: 170,000,000 shares authorized; 49,537,267 and 32,525,356 shares issued at September 30, 2016 and December 31, 2015, respectively		495,371			325,252
Common stock to be issued		6,274,000			-
Additional paid-in capital		456,545,927			434,099,890
Treasury stock, at cost: 79,545 shares held		(8,034,244	)		(8,034,244	)
Accumulated deficit		(439,258,067	)		(432,478,339	)
Total stockholders’ equity (deficit)		16,022,987			(6,087,441	)
Total liabilities and stockholders’ equity (deficit)	$	24,756,984		$	5,826,315

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30, 2016			September 30, 2015			September 30, 2016			September 30, 2015
Revenues:
Product sales	$	-		$	-		$	-		$	47,712

Costs and expenses:
Cost of product sales		-			-			-			6,274
Research and development		1,013,929			942,338			3,395,362			3,030,648
General and administrative		676,927			673,910			3,356,804			2,459,024
		1,690,856			1,616,248			6,752,166			5,495,946

Interest expense, net		5,614			24,346			23,140			72,836
Change in fair value of contingent rights		(2,978	)		(35,690	)		4,422			(17,346	)

Net loss	$	(1,693,492	)	$	(1,604,904	)	$	(6,779,728	)	$	(5,503,724	)

Net loss per share (basic and diluted)	$	(0.03	)	$	(0.05	)	$	(0.15	)	$	(0.17	)
Weighted average number of common shares outstanding (basic and diluted)		49,227,983			32,445,811			44,132,599			32,445,811

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months Ended
	September 30, 2016			September 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(6,779,728	)	$	(5,503,724	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		47,963			50,771
Net gain on disposal of assets		(12,461	)		-
Stock-based compensation expense		2,201,401			1,193,419
Non-cash interest		21,015			67,950
Change in fair value of contingent rights		4,422			(17,346	)
Changes in operating assets and liabilities:
Accounts receivable		-			23,727
Prepaid expenses and other		40,840			(88,997	)
Accounts payable		34,793			46,645
Accrued liabilities		(7,486	)		5,285
Net cash used in operating activities		(4,449,241	)		(4,222,270	)

CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of furniture and equipment		158,446			-
Purchases of furniture and equipment		(159,244	)		(23,729	)
Net cash used in investing activities		(798	)		(23,729	)

CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuance costs		(72,087	)		-
Proceeds from sale of common stock		17,254,341
Proceeds from sale of common stock to be issued		6,274,000			-
Net cash provided by financing activities		23,456,254			-

Net increase (decrease) in cash and cash equivalents		19,006,215			(4,245,999	)
Cash and cash equivalents at beginning of period		5,131,114			10,669,919
Cash and cash equivalents at end of period	$	24,137,329		$	6,423,920

Supplemental disclosure of cash flow information:

Non-cash financing activity:
Partial settlement of contingent rights derivative	$	3,232,502		$	-

See accompanying condensed notes.

CASI PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016 (unaudited)

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of CASI Pharmaceuticals, Inc. and its subsidiaries (“CASI” or “the Company”), Miikana Therapeutics, Inc. (“Miikana”) and CASI Pharmaceuticals (Beijing) Co., Ltd. (“CASI China”). The Company previously operated under a different name prior to restructuring its business in 2012 in connection with an investment led by one of the Company’s largest stockholders. CASI China is a non-stock Chinese entity with 100% of its interest owned by CASI. CASI China received approval for a business license from the Beijing Industry and Commercial Administration in August 2012 and has operating facilities in Beijing. All inter-company balances and transactions have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, such condensed consolidated financial statements do not include all of the information and disclosures required by U.S. generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The accompanying December 31, 2015 financial information was derived from the Company’s audited financial statements in the Annual Report on Form 10-K for the year ended December 31, 2015. Operating results for the three and nine month periods ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in its Form 10-K for the year ended December 31, 2015.

Liquidity Risks and Management’s Plans

Since inception, the Company has incurred significant losses from operations and has incurred an accumulated deficit of $439.3 million. The Company restructured its business in 2012 in connection with an investment led by one of the Company’s largest stockholders, followed by implementation of a name change to reflect its core mission and business strategy. The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical activities. In September 2015, the Company entered into stock purchase agreements for a $25.1 million strategic financing, the closing of which was subject to certain regulatory and customary conditions. In January 2016, the Company completed the first closing and received approximately $10.3 million (“First Closing”). In June 2016, the Company completed the second closing and received approximately $6.0 million (“Second Closing”). In July 2016, the Company completed the third closing and received $1.0 million (“Third Closing”). In October 2016, the Company completed the final closing and received $7.8 million (“Final Closing”), together these closings are referred to as the Closings (see Note 5). The Final Closing included an investment from ETP Precision Medicine, LLC, a healthcare investment fund of which the Company’s Chairman serves as managing member. On October 24, 2016, the Company entered into and closed on a stock purchase agreement in a private placement with an accredited investor and received $3.0 million (“October Offering”) (see Note 5). Net proceeds of the Closings and the October Offering will be used to further fund the Company’s operations, accelerate its clinical and regulatory activities, expand its product pipeline, and support its marketing and commercial planning activities. As a result of the Closings and the October Offering, the Company believes that it has sufficient resources to fund its operations for at least the twelve months subsequent to September 30, 2016. As of September 30, 2016, approximately $6.2 million of the Company’s cash balance was held by CASI China. The Company intends to continue to exercise tight controls over operating expenditures and will continue to pursue opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive capital raising arrangements in China to support the Company’s dual-country approach to drug development.

License Arrangements and Acquisition of In-Process Research and Development

In September 2014, the Company acquired certain product rights and perpetual exclusive licenses from Spectrum Pharmaceuticals, Inc. and certain of its affiliates (together referred to as “Spectrum”) to develop and commercialize the following commercial oncology drugs and drug candidates in the greater China region (which includes China, Taiwan, Hong Kong and Macau) (the “Territories”):

MARQIBO^®(vinCRIStine sulfate LIPOSOME injection) (“Marqibo”);

ZEVALIN^®(ibritumomab tiuxetan) (“Zevalin”); and

EVOMELA^®(melphalan) for Injection (“Evomela”).

CASI is responsible for developing and commercializing these three drugs in the Territories, including the submission of import drug registration applications and conducting confirmatory clinical trials as needed.

The Company is in various stages of the regulatory and development process to obtain marketing approval for MARQIBO^®, ZEVALIN^®and EVOMELA^® in its territorial region, with ZEVALIN^® commercially available in Hong Kong. In January 2016, the China Food and Drug Administration (CFDA) accepted for review the Company’s import drug registration application for MARQIBO^® and currently is in the quality testing phase of the regulatory review. On March 10, 2016, Spectrum received notification from the U.S. Food and Drug Administration (FDA) of the grant of approval of its New Drug Application (NDA) for EVOMELA^® primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. The Company is working with its partner to finalize the CFDA submission for EVOMELA^®and expects to file by the end of 2016.

As consideration for the acquisition from Spectrum, the Company issued a total 5,405,382 shares of its common stock, a $1.5 million 0.5% secured promissory note originally due in March 2016, and certain contingent rights (“Contingent Rights”) to purchase additional shares of its common stock, which Contingent Rights expire upon the occurrence of certain events. The note was subsequently amended to extend the due date to March 2017 (see Note 3). The Company accounted for the acquisition of the product rights and licenses as an asset acquisition and, accordingly, recorded the acquired product rights and licenses at their estimated fair values based on the fair value of the consideration exchanged (including transaction costs) of approximately $19.7 million. Because the products underlying the acquired product rights and licenses have not reached technological feasibility and have no alternative uses, they are considered “in-process research and development” costs; as such, the Company expensed the total purchase price at the acquisition date as acquired in-process research and development in the consolidated statement of operations for the year ended December 31, 2014.

The fair value of the common stock issued was based on the closing market price of the Company’s common stock on the acquisition date. The fair value of the promissory note was measured using Level 3 unobservable inputs (see Note 4) including primarily the Company’s estimated incremental borrowing rate as provided by a commercial lending institution.

The Contingent Rights provide Spectrum with the option to acquire, at a strike price of par value, a variable number of additional shares of common stock that allows Spectrum to maintain its fully-diluted ownership percentage for a certain time period and under certain terms and conditions. These Contingent Rights will expire on the earlier of raising an aggregate of $50 million or September 17, 2019 (subject to possible extension only for certain outstanding derivative securities). Based on the terms and conditions of the Contingent Rights, the Company has determined that the Contingent Rights are a derivative financial instrument that is not indexed to its common stock and therefore is required to be accounted for at fair value, initially and on a recurring basis. The fair value of the Contingent Rights was measured using Level 3 unobservable inputs; the unobservable inputs include estimates of the Company’s future capital requirements, and the timing, probability, size and characteristics of those capital raises, among other inputs. The total estimated fair value of the Contingent Rights was $6,167,142 and $9,395,222 as of September 30, 2016 and December 31, 2015, respectively; the change in fair value (see Note 4) is reflected as change in fair value of contingent rights in the accompanying condensed consolidated statements of operations.

As a result of the First Closing (see Note 5), Spectrum exercised its Contingent Rights and the Company issued Spectrum 1,688,877 shares of common stock in February 2016. As a result of the Second Closing (see Note 5), Spectrum exercised its Contingent Rights and the Company issued Spectrum 980,732 shares of common stock in July 2016. As a result of the Third Closing (see Note 5), Spectrum exercised its Contingent Rights and the Company issued Spectrum 164,526 shares of common stock in July 2016. The Company recorded a reduction to the contingent rights derivative liability and an increase to additional paid-in capital of $3,232,502 related to the partial settlement of the contingent rights derivative as a result of the First Closing, Second Closing and Third Closing, which is reflected in the accompanying condensed consolidated balance sheet as of September 30, 2016.

As a result of the Final Closing and the October Offering (see Note 5), Spectrum exercised its Contingent Rights and the Company issued Spectrum 1,789,062 shares of common stock in October 2016. In October 2016, the Company will record a reduction to the contingent rights derivative liability and an increase to additional paid-in-capital of $2,047,243 which will be reflected in the Company’s December 31, 2016 consolidated financial statements.

Note Payable

As part of the license arrangements with Spectrum (see Note 2), the Company issued to Spectrum a $1.5 million 0.5% secured promissory note originally due March 17, 2016. The promissory note was recorded initially at its fair value, giving rise to a discount of approximately $136,000; the promissory note is presented as note payable, net of discount in the accompanying condensed consolidated balance sheets. For the nine months ended September 30, 2016 and 2015, the Company recognized $21,015 and $67,950 of non-cash interest expense, respectively, related to the amortization of the debt discount, using the effective interest method. On September 28, 2015, the Company entered into a First Amendment to Secured Promissory Note (the “Amendment”) with Spectrum. Pursuant to the Amendment, the Company and Spectrum agreed to extend the maturity date of the note to March 17, 2017. All other terms remain the same.

Fair Value Measurements

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:

Level 1, defined as observable inputs such as quoted prices in active markets for identical assets;

Level 2, defined as observable inputs other than Level 1 prices such as quoted prices for similar assets; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company performs a detailed analysis of its assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair values are based on period-end statements supplied by the various banks and brokers that held the majority of the Company’s funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current assets and liabilities) approximates their carrying values because of their short-term nature.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:

The Contingent Rights issued to Spectrum in connection with the license arrangements (see Note 2) are considered derivative liabilities and were recorded initially at their estimated fair value, and are marked to market each reporting period until settlement. The fair value of the Contingent Rights was measured using Level 3 unobservable inputs; the unobservable inputs include estimates of the Company’s future capital requirements, and the timing, probability, size and characteristics of those capital raises, among other inputs. Generally, if the estimates of the size and probability of the Company’s future capital requirements increase, the fair value of the Contingent Rights will also increase.

The following table presents the Company’s financial liabilities accounted for at fair value on a recurring basis as of September 30, 2016 and December 31, 2015 by level within the fair value hierarchy:

	As of September 30, 2016
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	6,167,142	$	6,167,142

	As of December 31, 2015
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	9,395,222	$	9,395,222

The following table presents the changes in the Company’s financial liabilities accounted for at fair value on a recurring basis using Level 3 unobservable inputs:

December 31, 2015	$	9,395,222
Partial settlement of Contingent Rights		(3,232,502	)
Change in fair value of Contingent Rights		4,422
Balance at September 30, 2016	$	6,167,142

Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:

The promissory note issued to Spectrum in connection with the license arrangements (see Notes 2 and 3) was initially recorded at its fair value using Level 3 unobservable inputs including primarily the Company’s estimated incremental borrowing rate as provided by a commercial lending institution.

Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:

The Company does not have any non-financial assets and liabilities that are measured at fair value on a recurring basis.

Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:

The Company measures its long-lived assets, including property and equipment, at fair value on a non-recurring basis. These assets are recognized at fair value when they are deemed to be impaired. No such fair value impairment was recognized for the nine months ended September 30, 2016 and 2015.

Stockholders’ Equity

Securities Purchase Agreements

As described in Note 1, on September 20, 2015, the Company entered into stock purchase agreements with certain institutional and accredited investors (the “Investors”) for a $25.1 million financing. Pursuant to these agreements, the Company agreed to sell to the Investors in a private placement an aggregate of 20,658,434 shares of the Company’s common stock, at $1.19 per share, based on the closing bid price of the Company’s common stock on the Nasdaq Capital Market on September 18, 2015, and a total of 4,131,686 warrants, representing a 20% warrant coverage, with a purchase price of $0.125 per whole warrant share. The warrants become exercisable three months after issuance at $1.69 per share exercise price, and expire three years from the date the warrants become exercisable.

The offering closed after satisfaction of certain regulatory and customary closing conditions, with the net proceeds subject to payment of offering expenses, including fees and expenses.

On January 15, 2016, the Company completed the First Closing and received approximately $10.3 million and yielded approximately $10.2 million after offering expenses. The First Closing resulted in the issuance of 8,448,613 shares of Common Stock, priced at $1.19 per share, and 1,689,722 warrants, with a purchase price of $0.125 per warrant. The warrants became exercisable on April 15, 2016 at $1.69 per share exercise price, and will expire on April 15, 2019. The fair value of the warrants issued is $321,047, calculated using the Black-Scholes-Merton valuation model value of $0.19 with a contractual life of 3.25 years, an assumed volatility of 70.1%, and a risk-free interest rate of 1.08%.

On June 24, 2016, the Company completed the Second Closing and received approximately $6.0 million. The Second Closing resulted in the issuance of 4,906,118 shares of Common Stock, priced at $1.19 per share, and 981,223 warrants, with a purchase price of $0.125 per warrant. The warrants became exercisable on September 23, 2016 at $1.69 per share exercise price, and will expire on September 23, 2019. The fair value of the warrants issued is $431,738, calculated using the Black-Scholes-Merton valuation model value of $0.44 with a contractual life of 3.25 years, an assumed volatility of 70.4%, and a risk-free interest rate of 0.76%.

On July 5, 2016, the Company completed the Third Closing and received $1.0 million. The Third Closing resulted in the issuance of 823,045 shares of Common Stock, priced at $1.19 per share, and 164,609 warrants, with a purchase price of $0.125 per warrant. The warrants became exercisable on October 4, 2016 at $1.69 per share exercise price, and will expire on October 4, 2019. The fair value of the warrants issued is $67,490, calculated using the Black-Scholes-Merton valuation model value of $0.41 with a contractual life of 3.25 years, an assumed volatility of 70.6%, and a risk-free interest rate of 0.66%.

On October 3, 2016, the Company completed the Final Closing and received $7.8 million. The Final Closing resulted in the issuance of 6,480,655 shares of Common Stock, priced at $1.19 per share, and 1,296,129 warrants, with a purchase price of $0.125 per warrant. The warrants will become exercisable on January 2, 2017 at $1.69 per share exercise price, and will expire on January 2, 2020. The fair value of the warrants issued is $544,374, calculated using the Black-Scholes-Merton valuation model value of $0.42 with a contractual life of 3.25 years, an assumed volatility of 71.4%, and a risk-free interest rate of 0.91%. The Company received approximately $6.3 million of the $7.8 million proceeds from the Final Closing as of September 30, 2016 which is reflected as common stock to be issued on the September 30, 2016 condensed consolidated balance sheet.

The Company granted registration rights to the Investors and agreed to file a resale registration statement covering the shares of common stock and the shares of common stock underlying the warrants within 120 days of the Final Closing.

As described in Note 1, on October 24, 2016, the Company entered into and closed on a stock purchase agreement with an accredited investor, pursuant to which the Company agreed to sell to the investor in a private placement an aggregate of 2,469,135 shares of the Company’s Common Stock, priced at $1.190 per share, and 493,827 warrants, representing a 20% warrant coverage, with a purchase price of $0.125 per whole warrant share, for aggregate gross proceeds to the Company of $3.0 million. The warrants will become exercisable on January 23, 2017 at $1.69 per share exercise price, and will expire on January 23, 2020. The fair value of the warrants issued in the October Offering is $306,173, calculated using the Black-Scholes-Merton valuation model value of $0.62 with a contractual life of 3.25 years, an assumed volatility of 72.2%, and a risk-free interest rate of 1.00%.

The Company granted registration rights to the investor and agreed to file a resale registration statement covering the shares of common stock and the shares of common stock underlying the warrants within 120 days of the closing of the transaction.

Share-Based Compensation

The Company has adopted incentive and nonqualified stock option plans for executive, scientific and administrative personnel of the Company as well as outside directors and consultants. In June 2016, the Company’s shareholders approved an amendment to the 2011 Long-Term Incentive Plan, increasing the number of shares reserved for issuance from 8,230,000 to 11,230,000 shares of common stock to be available for grants and awards. As of September 30, 2016, there are 9,067,244 shares issuable under options previously granted and currently outstanding, with exercise prices ranging from $0.86 to $17.38. In 2016, the Company awarded options to officers and employees, covering up to 873,000 shares, in which vesting is subject to achievement of certain performance milestones. Options granted under the plans generally vest over periods varying from immediately to one to three years, are not transferable and generally expire ten years from the date of grant. As of September 30, 2016, 2,554,019 shares remained available for grant under the Company’s 2011 Long-Term Incentive Plan.

The Company records compensation expense associated with stock options and other equity-based compensation in accordance with provisions of authoritative guidance. Compensation costs are recognized over the requisite service period, which is generally the option vesting term of up to three years. Awards with performance conditions will be expensed if it is probable that the performance condition will be achieved. For the nine months ended September 30, 2016, $10,100 was expensed for share awards with performance conditions that became probable during that period. There was no expense recorded for share awards with performance conditions during the nine months ended September 30, 2015.

The Company’s net loss for the nine months ended September 30, 2016 and 2015 includes non-cash compensation expense of $2,201,401 and $1,193,419, respectively, related to the Company’s share-based compensation awards. The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:

	NINE MONTH PERIOD ENDED SEPTEMBER 30,
	2016		2015
Research and development	$	578,626	$	569,791
General and administrative		1,622,775		623,628
Share-based compensation expense	$	2,201,401	$	1,193,419
Net share-based compensation expense, per common share:
Basic and diluted	$	0.05	$	0.04

The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of stock options granted to employees. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award.

Following are the weighted-average assumptions used in valuing the stock options granted during the nine-month periods ended September 30, 2016 and 2015:

	NINE MONTH PERIOD ENDED SEPTEMBER 30,
	2016			2015
Expected volatility		83.03	%		85.28	%
Risk-free interest rate		1.31	%		1.58	%
Expected term of option		5.41 years			5.67 years
Forfeiture rate*		3.00	%		3.00	%
Expected dividend yield		0.00	%		0.00	%

* - Authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the nine-month periods ended September 30, 2016 and 2015, forfeitures were estimated at 3%.

The weighted average fair value of stock options granted during the nine-month periods ended September 30, 2016 and 2015 were $0.75 and $1.02, respectively.

A summary of the Company’s stock option plans and of changes in options outstanding under the plans for the nine months ended September 30, 2016 is as follows:

	Number of Options			Weighted Average Exercise Price
Outstanding at January 1, 2016		6,694,744		$	1.99
Granted		3,336,357		$	0.95
Exercised		-		$	-
Expired		(836,062	)	$	2.20
Forfeited		(127,795	)	$	1.33
Outstanding at September 30, 2016		9,067,244		$	1.60
Vested and expected to vest at September 30, 2016		8,968,117		$	1.61
Exercisable at September 30, 2016		5,763,002		$	1.90

There were no option exercises during the three or nine months ended September 30, 2016 or 2015.

Income Taxes

At December 31, 2015, the Company had a $3.1 million unrecognized tax benefit. The Company recorded a full valuation allowance on the net deferred tax asset recognized in the consolidated financial statements as of December 31, 2015.

During the nine months ended September 30, 2016, there were no material changes to the measurement of unrecognized tax benefits in various taxing jurisdictions. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense.

The tax returns for all years in the Company’s major tax jurisdictions are not settled as September 30, 2016. Due to the existence of tax attribute carryforwards (which are currently offset by a full valuation allowance), the Company treats all years’ tax positions as unsettled due to the taxing authorities’ ability to modify these attributes.

Related Party Transactions

In June 2016, under a supply agreement with Spectrum, the Company received a shipment of MARQIBO^® in China for quality testing purposes to support CASI’s application for import drug registration. The CEO of Spectrum is also a board member of CASI. The total cost of the materials was $133,770 which is included in research and development expense for the nine months ended September 30, 2016.

In 2015, the Company began utilizing the services of Crown Biosciences, Inc. (“Crown Bio”) to perform certain research and development testing. The CEO of Crown Bio is also a board member of CASI. The total value of the services is $66,545, of which $16,648 was payable as of September 30, 2016. The research and development expense recognized for the services provided for the nine months ended September 30, 2016 and 2015 was $28,648 and $24,750, respectively.

In October 2015, the Company entered into a material transfer and research agreement with Origene Technologies, Inc. (“Origene”) for certain research materials. The CEO of Origene is also the Chairman of the Board of CASI. No materials have been purchased as of September 30, 2016, and there is no minimum commitment associated with this agreement.

As described in Note 1, in January, June, July and October 2016, the Company conducted a series of closings for a $25.1 million financing previously announced in September 2015. Participants in the offering included ETP Precision Medicine, LLC, a healthcare investment fund. The managing member of ETP Precision Medicine, LLC is also the Chairman of the Company.

New Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact the Company’s condensed consolidated financial statements.

In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2014-15, Presentation of Financial Statements – Going Concern. The new standard requires management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term “substantial doubt,” 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is not permitted. The Company does not expect that this new accounting pronouncement will have an impact on its financial statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which provides guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. In July 2015, the FASB delayed the effective date of this standard by one year. The new standard will be effective for the Company’s reporting year beginning on January 1, 2018, and early adoption of the standard as of January 1, 2017 is permitted. In March 2016, the FASB issued an accounting standard update to clarify the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued an accounting standard update to clarify the identification of performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. In May 2016, the FASB issued an accounting standard update to clarify guidance in certain areas and add some practical expedients to the guidance. The amendments in these 2016 updates do not change the core principle of the previously issued guidance in May 2014. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In November 2015, the FASB issued new guidance on the balance sheet classification of deferred taxes. To simplify presentation, the new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The accounting standard is effective for public business entities for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is permitted. The Company has not yet adopted this pronouncement but does not expect it to have any impact on its consolidated financial statements.

In January 2016, the FASB issued a new accounting standard on recognition and measurement of financial assets and financial liabilities. The accounting standard primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, it includes a clarification related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2017. Early adoption is permitted for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact, if any, that the pronouncement will have on the consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU 2016-02 supersedes existing lease guidance, including Accounting Standards Codification (ASC) 840 - Leases. Among other things, the new standard requires recognition of a right-of-use asset and liability for future lease payments for contracts that meet the definition of a lease. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. The standard must be applied using a modified retrospective approach. The Company is currently evaluating the effect that the adoption of this ASU will have on its financial statements.

In March 2016, the FASB issued an accounting standard update which simplified several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. The Company does not expect that the adoption of this ASU will have a material impact on its financial statements.

In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU 2016-15). ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years and earlier adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on its financial statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

OVERVIEW

We are a late-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on delivering innovative drugs to China. We intend to execute our plan to become a leading fully-integrated pharmaceutical company conducting clinical development activities internationally, primarily in China, U.S. Canada, and commercialize in China, and with partners for the rest of the world.

Our pipeline features (1) our lead proprietary drug candidate, ENMD-2076, in multiple Phase 2 clinical trials, (2) MARQIBO^®, ZEVALIN^®and EVOMELA^®, all FDA approved drugs in-licensed from Spectrum for China regional rights, and currently in various stages in the regulatory process for market approval in China, and (3) proprietary early-stage candidates in preclinical development. We believe our pipeline reflects a risk-balanced approach between products in various stages of development, and between products that we develop ourselves and those that we develop with our partners for the China regional market. We intend to continue building a significant product pipeline of innovative drug candidates that we will commercialize alone in China and with partners for the rest of the world. For ENMD-2076, our current development is focused on niche and orphan indications. For in-licensed products, the Company uses a market-oriented approach to identify pharmaceutical candidates that it believes have the potential for gaining widespread market acceptance, either globally or in China, and for which development can be accelerated under the Company’s drug development strategy.

Our primary research and development focus is on oncology therapeutics. Our strategy is to develop innovative drugs that are potential first-in-class or market-leading compounds for treatment of cancer. The implementation of our plans will include leveraging our resources in both the United States and China. In order to capitalize on the drug development and capital resources available in China, the Company is doing business in China through its wholly-owned Chinese subsidiary that will execute the China portion of the Company’s drug development strategy, including conducting clinical trials in China, pursuing local funding opportunities and strategic collaborations, and implementing the Company’s plan for development and commercialization in the China market.

As a result of the Closings and the October Offering, the Company believes that it has sufficient resources to fund its operations for at least the twelve months subsequent to September 30, 2016. We intend to continue to exercise tight controls over operating expenditures. In developing drug candidates, we intend to use and leverage resources available to us in both the United States and China. We intend to pursue additional financing opportunities as well as opportunities to raise capital through forms of non- or less- dilutive arrangements, such as partnerships and collaborations with organizations that have capabilities and/or products that are complementary to our capabilities and products in order to continue the development of our product candidates that we intend to pursue to commercialization. However, there can be no assurance that adequate additional financing under such arrangements will be available to us on terms that we deem acceptable, if at all.

Additional funds raised by issuing equity securities may result in dilution to existing stockholders.

CRITICAL ACCOUNTING POLICIES AND THE USE OF ESTIMATES

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Our critical accounting policies, including the items in our financial statements requiring significant estimates and judgments, are as follows:

Revenue Recognition – We recognize revenue in accordance with the provisions of authoritative guidance issued, whereby revenue is not recognized until it is realized or realizable and earned. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the buyer is fixed and determinable and collectibility is reasonably assured.

Research and Development – Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with preclinical testing and clinical trials of our product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses. Research and development costs are expensed as incurred.

Expenses for Clinical Trials – Expenses for clinical trials are incurred from planning through patient enrollment to reporting of the data. We estimate expenses incurred for clinical trials that are in process based on patient enrollment and based on clinical data collection and management. Costs that are associated with patient enrollment are recognized as each patient in the clinical trial completes the enrollment process. Estimated clinical trial costs related to enrollment can vary based on numerous factors, including expected number of patients in trials, the number of patients that do not complete participation in a trial, and when a patient drops out of a trial. Costs that are based on clinical data collection and management are recognized in the reporting period in which services are provided. In the event of early termination of a clinical trial, we accrue an amount based on estimates of the remaining non-cancelable obligations associated with winding down the clinical trial.

Stock-Based Compensation – All share-based payment transactions are recognized in the consolidated financial statements at their fair values. Compensation expense associated with service, performance, market condition-based stock options and other equity-based compensation is recorded in accordance with provisions of authoritative guidance. The fair value of awards whose fair values are calculated using the Black-Scholes option pricing model is generally being amortized on a straight-line basis over the requisite service period and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period. The fair value of awards with market conditions, which are valued using a binomial model, is being amortized based upon the estimated derived service period. Share-based awards granted to employees with a performance condition are measured based on the probable outcome of that performance condition during the requisite service period. Such an award with a performance condition will be expensed if it is probable that a performance condition will be achieved. For the nine months ended September 30, 2016, $10,100 was expensed for share awards with performance conditions that became probable during that period. For the nine months ended September 30, 2015, no expense was recorded for share awards with performance conditions. Using the straight-line expense attribution method over the requisite service period, which is generally the option vesting term ranging from immediately to one to three years, share-based compensation expense recognized for the nine months ended September 30, 2016 and 2015 totaled approximately $2,201,000 and $1,193,000, respectively.

The determination of fair value of stock-based payment awards on the date of grant using the Black-Scholes valuation model is affected by our stock price, as well as the input of other subjective assumptions. These assumptions include, but are not limited to, the expected forfeiture rate and expected term of stock options, risk free interest rate and our expected stock price volatility over the term of the awards. Changes in the assumptions can materially affect the fair value estimates.

Any future changes to our share-based compensation strategy or programs would likely affect the amount of compensation expense recognized.

Fair Value Measurements – At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3 in accordance with the hierarchy established by U.S. GAAP. As of September 30, 2016, we remeasured the Contingent Rights and will continue to do so at every balance sheet date until settlement. In measuring the fair value of both financial instruments we used Level 3 unobservable inputs, including such inputs as our estimated borrowing rate and our future capital requirements, and the timing, probability, size and characteristics of those capital raises, among other inputs.

RESULTS OF OPERATIONS

For the Three and Nine Months Ended September 30, 2016 and September 30, 2015.

Revenues and Cost of Product Sales. Revenues for the nine months ended September 30, 2015 were approximately $48,000. There was no revenue recorded for the three months ended September 30, 2015 and the three and nine months ended September 30, 2016. Our product sales in 2015 related to the dosing of Zevalin to patients in Hong Kong. The cost of sales for the nine months ended September 30, 2015 was $6,274 and includes the cost of the Zevalin Kit and Isotope purchase.

Research and Development Expenses. Our research and development expenses for the three and nine months ended September 30, 2016 totaled approximately $1,014,000 and $3,395,000, respectively. Research and development expenses for the corresponding 2015 periods were $942,000 and $3,031,000, respectively. Included in our R&D expenses for the three-month period ended September 30, 2016 are direct project costs of $452,000 for ENMD-2076, $65,000 for drugs in-licensed from Spectrum, and $229,000 for preclinical development activities in China. The 2015 research and development expenses for the comparable period included $328,000 for ENMD-2076, $115,000 for drugs in-licensed from Spectrum, and $176,000 for preclinical development activities in China. Research and development expenses totaling $3,395,000 for the nine-month period ended September 30, 2016 included direct project costs of $1,269,000 related to ENMD-2076, $375,000 for drugs in-licensed from Spectrum, and $585,000 for preclinical development activities in China. The 2015 research and development expenses for the comparable period totaled $3,031,000 and included $1,144,000 for ENMD-2076, 258,000 for drugs in-licensed from Spectrum, and $584,000 for preclinical development activities in China. The overall increase in research and development costs in the three and nine month periods ended September 30, 2016, as compared to same periods in 2015, reflects increased patient enrollment costs associated with our Phase 2 clinical trial in fibrolamellar carcinoma (FLC).

At September 30, 2016, and, since acquired, accumulated direct project expenses for ENMD-2076 totaled $27,229,000, $761,000 for drugs in-licensed from Spectrum, and for preclinical development activities in China, accumulated project expenses totaled $1,798,000. Our research and development expenses also include non-cash stock-based compensation totaling $61,000 and $579,000 for the three and nine months ended September 30, 2016, respectively, and $148,000 and $570,000 for the corresponding 2015 periods, respectively. The balance of our research and development expenditures includes facility costs and other departmental overhead, and expenditures related to the non-clinical support of our programs.

We expect the majority of our research and development expenses in 2016 to be devoted to the development of our ENMD-2076 program, our early-stage candidates in preclinical development, and advancing our in-licensed products towards market approval in China. We expect our expenses in 2016 to increase based on our clinical development plan. Completion of clinical development may take several years or more, but the length of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate.

We estimate that clinical trials of the type we generally conduct are typically completed over the following timelines:

Global FDA Trial:

*CLINICAL PHASE*		*ESTIMATED* *COMPLETION* *PERIOD*
Phase 1		1-2 Years
Phase 2		2-3 Years
Phase 3		2-4 Years

Local CFDA Trial:

*CLINICAL PHASE*		*ESTIMATED* *COMPLETION* *PERIOD*
Phase 1		1 Year
Phase 2		2 Years
Phase 3		2-3 Years

The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during the clinical trial protocol, including, among others, the following:

the number of patients that ultimately participate in the trial;

the duration of patient follow-up that seems appropriate in view of the results;

the number of clinical sites included in the trials; and

the length of time required to enroll suitable patient subjects.

We test our potential product candidates in numerous preclinical studies to identify indications for which they may be product candidates. We may conduct multiple clinical trials to cover a variety of indications for each product candidate. As we obtain results from trials, we may elect to discontinue clinical trials for certain indications in order to focus our resources on more promising indications.

Our proprietary product candidates have also not yet achieved regulatory approval, which is required before we can market them as therapeutic products. In order to proceed to subsequent clinical trial stages and to ultimately achieve regulatory approval, regulatory agencies must conclude that our clinical data establish safety and efficacy. Historically, the results from preclinical testing and early clinical trials have often not been predictive of results obtained in later clinical trials. A number of new drugs and biologics have shown promising results in clinical trials, but subsequently failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals.

Our business strategy includes being opportunistic with collaborative arrangements with third parties to complete the development and commercialization of our product candidates. In the event that third parties take over the clinical trial process for one of our product candidates, the estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in whole or in part, and how such arrangements would affect our capital requirements.

As a result of the uncertainties discussed above, among others, we are unable to estimate the duration and completion costs of our research and development projects. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. There can be no assurance that we will be able to successfully access external sources of financing in the future. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.

Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with internal and contract preclinical testing and clinical trials of our product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses. Overall research and development expenses increased to $1,014,000 during the three-months ended September 30, 2016 from $942,000 for the corresponding period in 2015. Research and development expenses increased to $3,395,000 during the nine months ended September 30, 2016 from $3,031,000 for the corresponding period in 2015. The fluctuations in research and development expenditures during the three and nine months ended September 30, 2016 were specifically impacted by the following:

Outside Services – In the three-month period ended September 30, 2016, we expended $58,000 on outside service activities versus $75,000 in the same 2015 period. The decrease in 2016 as compared to 2015 reflects higher regulatory costs in 2015 associated with the import drug registration applications in China for the drugs in-licensed from Spectrum. For the nine-month period ended September 30, 2016 outside services were $175,000 compared to $171,000 for the same 2015 period.

Clinical Trial Costs – Clinical trial costs, which include clinical site fees, monitoring costs and data management costs, increased to $340,000 in the three months ended September 30, 2016 from $174,000 in the three-month period ended September 30, 2015. Clinical trial costs for the nine-month period ended September 30, 2016 increased to $899,000 from $683,000 for the comparable 2015 period. This increase primarily relates to patient costs and clinical trial management costs associated with our Phase 2 clinical trial in FLC during the 2016 period.

Contract Manufacturing Costs – The costs of manufacturing the material used in clinical trials for our product candidates is reflected in contract manufacturing. These costs include bulk manufacturing, encapsulation and fill and finish services, product release costs and storage fees. Contract manufacturing costs for the three months ended September 30, 2016 increased to $24,000 from $15,000 during the same period in 2015. For the nine-month period ended September 30, 2016, manufacturing costs increased to $196,000 from $142,000 for the comparable 2015 period. The increase primarily reflects costs associated with the purchase of MARQIBO^® in China for quality testing purposes to support CASI’s application for import drug registration in June 2016.

Personnel Costs – Personnel costs decreased to $367,000 in the three-month period ended September 30, 2016 from $413,000 in the corresponding 2015 period. This variance is primarily attributed to a decrease in non-cash stock-based compensation expense of $87,000 during the 2016 period. For the nine-month period ended September 30, 2016, personnel costs increased in 2016 to $1,439,000 from $1,289,000 for the corresponding 2015 period. This variance is attributed to increased salary and benefit costs associated with employees in China.

Also reflected in our 2016 research and development expenses for the three-month period ended September 30, 2016 are outsourced consultant costs of $71,000 and facility and related expenses of $73,000. In the corresponding 2015 period, these expenses totaled $87,000 and $111,000, respectively. For the nine-month period ended September 30, 2016, outsourced consultant costs were $231,000 and facility and related expenses were $251,000. In the corresponding 2015 period, these expenses totaled $207,000 and $286,000, respectively. The variance in outsourced consultant costs reflect the timing of clinical trial management, including site visits, and regulatory activities. The decrease in facility and related expenses in the 2016 period relates to a decrease in leased lab equipment in China during that period.

General and Administrative Expenses. General and administrative expenses include compensation and other expenses related to finance, business development and administrative personnel, board of directors, professional services, patent costs and facilities.

General and administrative expenses increased slightly to $677,000 in the three-month period ended September 30, 2016 from $674,000 in the corresponding 2015 period. The increase in the third quarter of 2016, compared to the 2015 period, is primarily related to an increase in salary and benefits associated with a new business development employee in the U.S. during the 2016 period, offset by a decrease in outside professional fees. For the nine-month period ended September 30, 2016, general and administrative expenses increased in 2016 to $3,357,000 from $2,459,000 for the corresponding 2015 period. The increase in the 2016 period, compared to the 2015 period is primarily related to an increase in stock-based compensation expense of $999,000 primarily related to stock options awarded in connection with the closings of the Company’s strategic financing in 2016, as well as an increase in salary and benefits associated with a new business development employee in the U.S. during the 2016 period. This increase was offset by decreases in outside professional fees and travel related costs associated with business development and investor relations activities during the 2015 period.

Interest expense, net. Interest expense, net for three months ended September 30, 2016 and 2015 was $5,614 and $24,346, respectively. This includes interest on our note payable of $1,875 for both periods; non-cash interest of $7,005 and $22,650, respectively, representing the amortization of the debt discount; offset by interest income of $3,266 and $179, respectively. Interest expense, net for the nine months ended September 30, 2016 and 2015 was $23,140 and $72,836, respectively. This includes interest on our note payable of $5,625 for both periods; non-cash interest of $21,015 and $67,950, respectively, representing the amortization of the debt discount; offset by interest income of $3,500 and $739, respectively.

Change in fair value of contingent rights. The Contingent Rights issued to Spectrum in connection with the license arrangements are considered derivative liabilities and were recorded initially at their estimated fair value, and are marked to market each reporting period until settlement. The change in fair value of the Contingent Rights for the three and nine months ended September 30, 2016 was $2,978 and $4,422, respectively. The change in fair value of the Contingent Rights for the three and nine months ended September 30, 2015 was $35,690 and $17,346, respectively.

LIQUIDITY AND CAPITAL RESOURCES

To date, we have been engaged primarily in research and development activities. As a result, we have incurred and expect to continue to incur operating losses in 2016 and the foreseeable future before we commercialize any products. Based on our current plans, we expect our current available cash and cash equivalents to meet our cash requirements for at least the twelve months subsequent to September 30, 2016.

We will require significant additional funding to fund operations until such time, if ever, we become profitable. We intend to augment our cash balances by pursuing other forms of capital infusion, including strategic alliances or collaborative development opportunities with organizations that have capabilities and/or products that are complementary to our capabilities and products in order to continue the development of our potential product candidates that we intend to pursue to commercialization. If we seek strategic alliances, licenses, or other alternative arrangements, such as arrangements with collaborative partners or others, to raise further financing, we may need to relinquish rights to certain of our existing product candidates, or products we would otherwise seek to develop or commercialize on our own, or to license the rights to our product candidates on terms that are not favorable to us.

We will continue to seek to raise additional capital to fund our research and development and advance the clinical development of ENMD-2076 and new product candidates, if any. We intend to explore one or more of the following alternatives to raise additional capital:

selling additional equity securities;

out-licensing product candidates to one or more corporate partners;

completing an outright sale of non-priority assets; and/or

engaging in one or more strategic transactions.

We also will continue to manage our cash resources prudently and cost-effectively.

There can be no assurance that adequate additional financing under such arrangements will be available to us on terms that we deem acceptable, if at all. If additional funds are raised by issuing equity securities, dilution to existing stockholders may result, or the equity securities may have rights, preferences, or privileges senior to those of the holders of our common stock. If we fail to obtain additional capital when needed, we may be required to delay or scale back our Phase 2 plans for ENMD-2076 or plans for other product candidates, if any.

At September 30, 2016, we had cash of $24,137,329 with working capital of $21,971,554. As of September 30, 2016, approximately $6.2 million of the Company’s cash balance was held by CASI China.

FINANCING ACTIVITIES

As discussed above, on January 15, 2016, the Company completed the First Closing and received approximately $10.3 million and yielded approximately $10.2 million after offering expenses. The First Closing resulted in the issuance of 8,448,613 shares of Common Stock, priced at $1.19 per share, and 1,689,722 warrants, with a purchase price of $0.125 per warrant. The warrants became exercisable on April 15, 2016 at $1.69 per share exercise price, and will expire on April 15, 2019. The fair value of the warrants issued is $321,047, calculated using the Black-Scholes-Merton valuation model value of $0.19 with a contractual life of 3.25 years, an assumed volatility of 70.1%, and a risk-free interest rate of 1.08%.

On October 24, 2016, the Company completed the October Offering and received $3.0 million. The October Offering resulted in the issuance of 2,469,135 shares of Common Stock, priced at $1.19 per share, and 1,296,129 warrants, with a purchase price of $0.125 per warrant. The warrants will become exercisable on January 23, 2017 at $1.69 per share exercise price, and will expire on January 23, 2020. The fair value of the warrants issued in the October Offering is $306,173, calculated using the Black-Scholes-Merton valuation model value of $0.62 with a contractual life of 3.25 years, an assumed volatility of 72.2%, and a risk-free interest rate of 1.00%.

INFLATION AND INTEREST RATE CHANGES

Management does not believe that our working capital needs are sensitive to inflation and changes in interest rates.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The primary objective of our investment activities is to preserve our capital until it is required to fund operations while at the same time maximizing the income we receive from our investments without incurring investment market volatility risk. Our investment income is sensitive to the general level of U.S. interest rates. In this regard, changes in the U.S. interest rates affect the interest earned on our cash and cash equivalents. Due to the short-term nature of our cash and cash equivalent holdings, a 10% movement in market interest rates would not materially impact on the total fair market value of our portfolio as of September 30, 2016.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s Chief Executive Officer and Principal Accounting Officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) were effective as of September 30, 2016 to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to the Company’s management, including its Chief Executive Officer and Principal Accounting Officer, as appropriate to allow timely decisions regarding required disclosure.

We believe that a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting that occurred during the quarter ended September 30, 2016 that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are subject in the normal course of business to various legal proceedings in which claims for monetary or other damages may be asserted. Management does not believe such legal proceedings, unless otherwise disclosed herein, are material.

ITEM 1A. RISK FACTORS

For information regarding factors that could affect the Company’s results of operations, financial condition and liquidity, see the risk factors discussion set forth in Item 1A of CASI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and the information under “Special Note Regarding Forward-Looking Statements” included in this report. There have been no material changes to our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. REMOVED AND RESERVED

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

4.1		Form of Common Stock Purchase Warrant (included in Exhibit 10.1) (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on November 13, 2015)
10.1		Form of Securities Purchase Agreement, dated September 20, 2015, by and among CASI Pharmaceuticals, Inc. and the investors thereto (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on November 13, 2015)
31.1		Rule 13a-14(a) Certification of Chief Executive Officer*
31.2		Rule 13a-14(a) Certification of Principal Accounting Officer*
32.1		Section 1350 Certification of Chief Executive Officer*
32.2		Section 1350 Certification of Principal Accounting Officer*
101		The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, formatted in eXtensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at September 30, 2016 and December 31, 2015, (ii) Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2016 and 2015, (iii) Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and 2015 and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.*

* Filed Herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CASI PHARMACEUTICALS, INC.
		(Registrant)


Date: November 14, 2016		/s/ Ken K. Ren
		Ken K. Ren
		Chief Executive Officer


Date: November 14, 2016		/s/ Sara B. Capitelli
		Sara B. Capitelli
		Principal Accounting Officer

EXHIBIT INDEX

4.1		Form of Common Stock Purchase Warrant (included in Exhibit 10.1) (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on November 13, 2015)
10.1		Form of Securities Purchase Agreement, dated September 20, 2015, by and among CASI Pharmaceuticals, Inc. and the investors thereto (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on November 13, 2015)
31.1		Rule 13a-14(a) Certification of Chief Executive Officer*
31.2		Rule 13a-14(a) Certification of Principal Accounting Officer*
32.1		Section 1350 Certification of Chief Executive Officer*
32.2		Section 1350 Certification of Principal Accounting Officer*
101		The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, formatted in eXtensible Business Reporting Language (XBRL): (i) Unaudited Condensed Consolidated Balance Sheets at September 30, 2016 and December 31, 2015, (ii) Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2016 and 2015, (iii) Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and 2015 and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.*

* Filed Herewith

EX-31.1 2 v452325_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Ken K. Ren, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CASI Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2016

/s/ Ken K. Ren
Ken K. Ren
Chief Executive Officer

EX-31.2 3 v452325_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL ACCOUNTING OFFICER

I, Sara B. Capitelli, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CASI Pharmaceuticals, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2016

/s/ Sara B. Capitelli
Sara B. Capitelli
Principal Accounting Officer

EX-32.1 4 v452325_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION BY CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ken K. Ren, as Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

Date: November 14, 2016		/s/ Ken K. Ren
		Ken K. Ren Chief Executive Officer

EX-32.2 5 v452325_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION BY PRINCIPAL ACCOUNTING OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sara B. Capitelli, as Principal Accounting Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

Date: November 14, 2016		/s/ Sara B. Capitelli
		Sara B. Capitelli Principal Accounting Officer

EX-101.INS 6 casi-20160930.xml XBRL INSTANCE DOCUMENT 0000895051 2015-01-01 2015-09-30 0000895051 2016-01-01 2016-09-30 0000895051 2015-07-01 2015-09-30 0000895051 2016-07-01 2016-09-30 0000895051 2016-09-30 0000895051 2016-11-07 0000895051 2015-12-31 0000895051 2014-12-31 0000895051 2015-09-30 0000895051 casi:InvestorsMember 2015-09-30 0000895051 casi:CasiChinaMember 2016-09-30 0000895051 casi:SpectrumPharmaceuticalsMember 2014-01-01 2014-12-31 0000895051 casi:SpectrumPharmaceuticalsMember 2014-12-31 0000895051 casi:SpectrumMember 2016-02-01 2016-02-29 0000895051 casi:SpectrumMember casi:SecondClosingMember 2016-07-01 2016-07-31 0000895051 casi:FisrtSecondAndThirdClosingMember casi:SpectrumMember 2016-01-01 2016-09-30 0000895051 casi:FinalClosingMember us-gaap:SubsequentEventMember casi:SpectrumMember 2016-10-01 2016-10-31 0000895051 us-gaap:FairValueInputsLevel1Member 2016-09-30 0000895051 us-gaap:FairValueInputsLevel2Member 2016-09-30 0000895051 us-gaap:FairValueInputsLevel3Member 2016-09-30 0000895051 us-gaap:FairValueInputsLevel1Member 2015-12-31 0000895051 us-gaap:FairValueInputsLevel2Member 2015-12-31 0000895051 us-gaap:FairValueInputsLevel3Member 2015-12-31 0000895051 us-gaap:InvestorMember 2015-09-01 2015-09-20 0000895051 us-gaap:InvestorMember 2015-09-20 0000895051 casi:FirstClosingMember 2016-01-01 2016-01-15 0000895051 casi:FirstClosingMember 2016-01-15 0000895051 casi:SecondClosingMember 2016-06-01 2016-06-24 0000895051 casi:SecondClosingMember 2016-06-24 0000895051 casi:ThirdClosingMember 2016-07-01 2016-07-05 0000895051 casi:ThirdClosingMember 2016-07-05 0000895051 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0000895051 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0000895051 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0000895051 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0000895051 casi:LongTermIncentivePlan2011Member 2016-09-30 0000895051 casi:LongTermIncentivePlan2011Member us-gaap:MinimumMember 2016-01-01 2016-09-30 0000895051 casi:LongTermIncentivePlan2011Member us-gaap:MaximumMember 2016-01-01 2016-09-30 0000895051 casi:BoardStaffOfficersAndEmployeesMember 2016-01-01 2016-09-30 0000895051 us-gaap:MinimumMember casi:LongTermIncentivePlan2011Member 2016-06-30 0000895051 us-gaap:MaximumMember casi:LongTermIncentivePlan2011Member 2016-06-30 0000895051 us-gaap:PerformanceSharesMember 2016-01-01 2016-09-30 0000895051 casi:CrownBiosciencesIncMember 2016-01-01 2016-09-30 0000895051 casi:CrownBiosciencesIncMember 2016-09-30 0000895051 casi:CrownBiosciencesIncMember 2015-01-01 2015-09-30 0000895051 casi:ContingentRightsMember 2016-01-01 2016-09-30 0000895051 casi:SpectrumMember 2016-01-01 2016-09-30 0000895051 us-gaap:SubsequentEventMember casi:FinalClosingMember 2016-10-01 2016-10-03 0000895051 us-gaap:SubsequentEventMember casi:FinalClosingMember 2016-10-03 0000895051 us-gaap:SubsequentEventMember 2016-10-01 2016-10-24 0000895051 us-gaap:SubsequentEventMember 2016-10-24 0000895051 casi:SpectrumMember casi:ThirdClosingMember 2016-07-01 2016-07-31 0000895051 casi:SpectrumPharmaceuticalsMember 2016-09-30 0000895051 casi:SpectrumPharmaceuticalsMember 2016-01-01 2016-09-30 0000895051 casi:FinalClosingMember 2016-01-01 2016-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

24137329

5131114

401080

438231

24538409

5569345

184090

218796

34485

38174

24756984

5826315

918892

884100

161978

169464

2566855

1053564

456545927

434099890

8034244

-439258067

-432478339

16022987

-6087441

24756984

5826315

8733997

11913756

6167142

9395222

1464970

495371

325252

1485985

3030648

3395362

2459024

3356804

-72836

-23140

-5503724

-6779728

-0.17

-0.15

32445811

44132599

-17346

4422

6274

47712

942338

1013929

673910

676927

-24346

-5614

-1604904

-1693492

-0.05

-0.03

32445811

49227983

-35690

-2978

50771

47963

1193419

2201401

-23727

88997

-40840

46645

34793

5285

-7486

-4222270

-4449241

23729

159244

-23729

-798

-4245999

19006215

10669919

6423920

67950

21015

12461

158446

72087

17254341

23456254

3232502

1 25100000

6200000

5405382

0.005

1500000

19700000

6167142

9395222

1688877

980732

3232502

1789062

2047243

67950

21015

136000

6167142

9395222

4422

0.2 0.125 1.19

1.69

25100000 1689722 0.125

8448613

1.19

321047 0.19

P3Y3M

0.701

0.0108

4906118

1.19

0.125 431738 0.44

P3Y3M

0.704

0.0076

981223

823045

1.19

0.125 67490 0.41

P3Y3M

0.706

0.0066

164609

569791

623628

578626

1622775

0.04 0.05

2554019

9067244

0.86

17.38

873000

8230000

11230000

10100

0.8303

0.0131

0.8528

0.0158

0.03 0.03

P5Y4M28D

P5Y8M1D

0.03

0.75

1.02

3336357

836062

127795

8968117

5763002

0.95

2.2

1.33

1.61

1.9

6694744

9067244

1.99

1.6

3100000

66545

28648

16648

24750

10-Q false 2016-09-30 2016 Q3 CASI Pharmaceuticals, Inc. 0000895051 --12-31 Smaller Reporting Company CASI 60196574

1.00

5000000

0.01

170000000

49537267

32525356

1690856

1616248

6752166

5495946

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Basis of Presentation</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying condensed consolidated financial statements include the accounts of CASI Pharmaceuticals, Inc. and its subsidiaries (“CASI” or “the Company”), Miikana Therapeutics, Inc. (“Miikana”) and CASI Pharmaceuticals (Beijing) Co., Ltd. (“CASI China”). The Company previously operated under a different name prior to restructuring its business in 2012 in connection with an investment led by one of the Company’s largest stockholders. CASI China is a non-stock Chinese entity with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of its interest owned by CASI. CASI China received approval for a business license from the Beijing Industry and Commercial Administration in August 2012 and has operating facilities in Beijing. All inter-company balances and transactions have been eliminated in consolidation.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, such condensed consolidated financial statements do not include all of the information and disclosures required by U.S. generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The accompanying December 31, 2015 financial information was derived from the Company’s audited financial statements in the Annual Report on Form 10-K for the year ended December 31, 2015. Operating results for the three and nine month periods ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in its Form 10-K for the year ended December 31, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Liquidity Risks and Management’s Plans</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Since inception, the Company has incurred significant losses from operations and <font style="COLOR: black">has incurred an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">439.3</font> million.  </font> The Company restructured its business in 2012 in connection with an investment led by one of the Company’s largest stockholders, followed by implementation of a name change to reflect its core mission and business strategy. The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical activities. In September 2015, the Company entered into stock purchase agreements for a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25.1</font> million strategic financing, the closing of which was subject to certain regulatory and customary conditions. In January 2016, the Company completed the first closing and received approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.3</font> million (“First Closing”). In June 2016, the Company completed the second closing and received approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.0</font> million (“Second Closing”). In July 2016, the Company completed the third closing and received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million (“Third Closing”). In October 2016, the Company completed the final closing and received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.8</font> million (“Final Closing”), together these closings are referred to as the Closings (see Note 5). The Final Closing included an investment from ETP Precision Medicine, LLC, a healthcare investment fund of which the Company’s Chairman serves as managing member. On October 24, 2016, the Company entered into and closed on a stock purchase agreement in a private placement with an accredited investor and received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.0</font> million (“October Offering”) (see Note 5). Net proceeds of the Closings and the October Offering will be used to further fund the Company’s operations, accelerate its clinical and regulatory activities, expand its product pipeline, and support its marketing and commercial planning activities. As a result of the Closings and the October Offering, the Company believes that it has sufficient resources to fund its operations for at least the twelve months subsequent to September 30, 2016. As of September 30, 2016, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.2</font> million of the Company’s cash balance was held by CASI China. The Company intends to continue to exercise tight controls over operating expenditures and will continue to pursue opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive capital raising arrangements in China to support the Company’s dual-country approach to drug development.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

March 2017

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">4.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Fair Value Measurements</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Level 1, defined as observable inputs such as quoted prices in active markets for identical assets;</font></div> </td> </tr> </table> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"> </font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Level 2, defined as observable inputs other than Level 1 prices such as quoted prices for similar assets; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</font></div> </td> </tr> </table> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"> </font></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ·</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company performs a detailed analysis of its assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair values are based on period-end statements supplied by the various banks and brokers that held the majority of the Company’s funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current assets and liabilities) approximates their carrying values because of their short-term nature.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Contingent Rights issued to Spectrum in connection with the license arrangements (see Note 2) are considered derivative liabilities and were recorded initially at their estimated fair value, and are marked to market each reporting period until settlement. The fair value of the Contingent Rights was measured using Level 3 unobservable inputs; the unobservable inputs include estimates of the Company’s future capital requirements, and the timing, probability, size and characteristics of those capital raises, among other inputs. Generally, if the estimates of the size and probability of the Company’s future capital requirements increase, the fair value of the Contingent Rights will also increase.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table presents the Company’s financial liabilities accounted for at fair value on a recurring basis as of September 30, 2016 and December 31, 2015 by level within the fair value hierarchy:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%" colspan="11"> <div>As of September 30, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Liabilities - Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,167,142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,167,142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%" colspan="11"> <div>As of December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Liabilities - Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,395,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,395,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table presents the changes in the Company’s financial liabilities accounted for at fair value on a recurring basis using Level 3 unobservable inputs:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,395,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Partial settlement of Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,232,502)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Change in fair value of Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,422</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Balance at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,167,142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">   </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The promissory note issued to Spectrum in connection with the license arrangements (see Notes 2 and 3) was initially recorded at its fair value using Level 3 unobservable inputs including primarily the Company’s estimated incremental borrowing rate as provided by a commercial lending institution.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <u><font style="FONT-SIZE: 10pt">Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company does not have any non-financial assets and liabilities that are measured at fair value on a recurring basis.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company measures its long-lived assets, including property and equipment, at fair value on a non-recurring basis. These assets are recognized at fair value when they are deemed to be impaired. No such fair value impairment was recognized for the nine months ended September 30, 2016 and 2015.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table presents the Company’s financial liabilities accounted for at fair value on a recurring basis as of September 30, 2016 and December 31, 2015 by level within the fair value hierarchy:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%" colspan="11"> <div>As of September 30, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Liabilities - Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,167,142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,167,142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%" colspan="11"> <div>As of December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Liabilities - Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,395,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,395,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table presents the changes in the Company’s financial liabilities accounted for at fair value on a recurring basis using Level 3 unobservable inputs:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,395,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Partial settlement of Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,232,502)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Change in fair value of Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,422</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Balance at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,167,142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

133770

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">6.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Share-Based Compensation</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has adopted incentive and nonqualified stock option plans for executive, scientific and administrative personnel of the Company as well as outside directors and consultants. In June 2016, the Company’s shareholders approved an amendment to the 2011 Long-Term Incentive Plan, increasing the number of shares reserved for issuance from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,230,000</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,230,000</font> shares of common stock to be available for grants and awards. <font style="COLOR: black">As of September 30, 2016, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9,067,244</font> shares issuable under options previously granted and currently outstanding, with exercise prices ranging from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.86</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17.38</font>. In 2016, the Company awarded options to officers and employees, covering up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 873,000</font> shares, in which vesting is subject to achievement of certain performance milestones. Options granted under the plans generally vest over periods varying from immediately to one to three years, are not transferable and generally expire ten years from the date of grant. As of September 30, 2016, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,554,019</font> shares remained available for grant under the Company’s 2011 Long-Term Incentive Plan.</font></font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company records compensation expense associated with stock options and other equity-based compensation in accordance with provisions of authoritative guidance. Compensation costs are recognized over the requisite service period, which is generally the option vesting term of up to three years. <font style="COLOR: #252525">Awards with</font> performance conditions <font style="COLOR: #252525"> will be expensed if it is probable that the</font> performance condition <font style="COLOR: #252525">will be achieved. For the nine months ended September 30, 2016, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,100</font> was expensed for share awards with performance conditions that became probable during that period. There was no expense recorded for share awards with performance conditions during the nine months ended September 30, 2015.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font>The Company’s net loss for the nine months ended September 30, 2016 and 2015 includes non-cash compensation expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,201,401</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,193,419</font>, respectively, related to the Company’s share-based compensation awards. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The</font></font> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense,</font></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font><font style="FONT-SIZE: 10pt"> </font></div> </div> </div> </div> </div> </div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%" colspan="5"> <div>NINE MONTH PERIOD ENDED</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%" colspan="5"> <div>SEPTEMBER 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>578,626</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>569,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1,622,775</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>623,628</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Share-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>2,201,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>1,193,419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Net share-based compensation expense, per common share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="15%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="15%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.05</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of stock options granted to employees. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Following are the weighted-average assumptions used in valuing the stock options granted during the nine-month periods ended September 30, 2016 and 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%" colspan="5"> <div>NINE MONTH PERIOD ENDED</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%" colspan="5"> <div>SEPTEMBER 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>83.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>85.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Expected term of option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>5.41 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>5.67 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeiture rate*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Expected dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">* - Authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the nine-month periods ended September 30, 2016 and 2015, forfeitures were estimated at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3</font>%.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The weighted average fair value of stock options granted during the nine-month periods ended September 30, 2016 and 2015 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.02</font>, respectively.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the Company’s stock option plans and of changes in options outstanding under the plans for the nine months ended September 30, 2016 is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Outstanding at January 1, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>6,694,744</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>1.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3,336,357</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>(836,062)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>(127,795)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Outstanding at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>9,067,244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Vested and expected to vest at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="15%"> <div>8,968,117</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Exercisable at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="15%"> <div>5,763,002</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">There were no option exercises during the three or nine months ended September 30, 2016 or 2015.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">The</font></font> <font style="FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt">compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense,</font></font><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font><font style="FONT-SIZE: 10pt"> </font></div> </div> </div> </div> </div> </div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%" colspan="5"> <div>NINE MONTH PERIOD ENDED</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%" colspan="5"> <div>SEPTEMBER 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>578,626</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>569,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1,622,775</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>623,628</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Share-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>2,201,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>1,193,419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Net share-based compensation expense, per common share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="15%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="15%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.05</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">A summary of the Company’s stock option plans and of changes in options outstanding under the plans for the nine months ended September 30, 2016 is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Outstanding at January 1, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>6,694,744</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>1.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3,336,357</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>0.95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>(836,062)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>2.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>(127,795)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Outstanding at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>9,067,244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Vested and expected to vest at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="15%"> <div>8,968,117</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Exercisable at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="15%"> <div>5,763,002</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

6480655

1.19

1296129 0.125 544374 0.42

P3Y3M

0.714

0.0091

0.2 0.125 306173 0.62

P3Y3M

0.722

0.0100

The warrants became exercisable on April 15, 2016 at $1.69 per share exercise price, and will expire on April 15, 2019. The warrants became exercisable on September 23, 2016 at $1.69 per share exercise price, and will expire on September 23, 2019. The warrants became exercisable on October 4, 2016 at $1.69 per share exercise price, and will expire on October 4, 2019. The warrants will become exercisable on January 2, 2017 at $1.69 per share exercise price, and will expire on January 2, 2020. The warrants will become exercisable on January 23, 2017 at $1.69 per share exercise price, and will expire on January 23, 2020.

164526

79545

50000000 These Contingent Rights will expire on the earlier of raising an aggregate of $50 million or September 17, 2019 (subject to possible extension only for certain outstanding derivative securities). 0.03

P1Y

P3Y

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>9.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">New Accounting Pronouncements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has implemented all new accounting pronouncements that are in effect and that may impact the Company’s condensed consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In August 2014, the Financial Accounting Standards Board (“FASB”) issued <font style="COLOR: black">Accounting Standard Update (“ASU”) 2014-15, <i>Presentation of Financial Statements  Going Concern</i>. The new standard</font> requires management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term “substantial doubt,” 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued.  The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is not permitted. The Company does not expect that this new accounting pronouncement will have an impact on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2014, the FASB issued <font style="COLOR: black">ASU 2014-09, <i>Revenue from Contracts with Customers,</i></font> which provides guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. <font style="COLOR: black">In July 2015, the FASB delayed the effective date of this standard by one year. The new standard will be effective for the Company’s reporting year beginning on January 1, 2018, and early adoption of the standard as of</font> January 1, 2017 is permitted. In March 2016, the FASB issued an accounting standard update to clarify the implementation guidance on principal versus agent considerations.  In April 2016, the FASB issued an accounting standard update to clarify the identification of performance obligations and the licensing implementation guidance, while retaining the related principles for those areas.  In May 2016, the FASB issued an accounting standard update to clarify guidance in certain areas and add some practical expedients to the guidance.  The amendments in these 2016 updates do not change the core principle of the previously issued guidance in May 2014. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In November 2015, the FASB issued new guidance on the balance sheet classification of deferred taxes. To simplify presentation, the new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet</font><font style="COLOR: #404041; FONT-SIZE: 10pt">. </font> <font style="COLOR: black; FONT-SIZE: 10pt">The accounting standard is effective for public business entities for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is permitted. The Company has not yet adopted this pronouncement but does not expect it to have any impact on its consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.75pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In January 2016, the FASB issued a new accounting standard on recognition and measurement of financial assets and financial liabilities. The accounting standard primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments.  In addition, it includes a clarification related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2017. Early adoption is permitted for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact, if any, that the pronouncement will have on the consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In February 2016, the FASB issued ASU No. 2016-02,  <i>Leases (Topic 842)</i>. ASU 2016-02 supersedes existing lease guidance, including Accounting Standards Codification (ASC) 840 - <i> Leases</i>. Among other things, the new standard requires recognition of a right-of-use asset and liability for future lease payments for contracts that meet the definition of a lease.</font> <font style="FONT-SIZE: 10pt">This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. <font style="COLOR: black">The standard must be applied using a modified retrospective approach.</font> The Company is currently evaluating the effect that the adoption of this ASU will have on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 25.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In March 2016, the FASB issued an accounting standard update which simplified several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods.</font> <font style="FONT-SIZE: 10pt">The Company does not expect that the adoption of this ASU will have a material impact on its financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In August 2016, the FASB issued Accounting Standards Update No. 2016-15, <i>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</i> (ASU 2016-15). ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years and earlier adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on its financial statements.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

6274000 0

1500000

493827

2469135

1.190

3000000

6000000

1000000

7800000

10300000

10200000

6274000 0 6300000 20658434 4131686 Authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the nine-month periods ended September 30, 2016 and 2015, forfeitures were estimated at 3%.

EX-101.SCH 7 casi-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - License Arrangements and Acquisition of In-Process Research and Development link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Note Payable link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Share-Based Compensation link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - New Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Basis of Presentation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - License Arrangements and Acquisition of In-Process Research and Development (Details Textual) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Note Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Fair Value Measurements (Details 1) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Share-Based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Share-Based Compensation (Details 2) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Share-Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 casi-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 casi-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 casi-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule Of Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Shedule of Description of Business and Basis of Presentation [Table] Legal Entity [Axis] Entity [Domain] Scenario [Axis] Scenario, Unspecified [Domain] Class of Stock [Domain] Stock Issued [Axis] Retained Earnings (Accumulated Deficit), Total Accumulated deficit Proceeds from Issuance or Sale of Equity, Total Proceeds from Issuance of Common Stock And Warrants Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] General and Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation, Total Stock-based compensation expense Net Share Based Compensation Expense Per Common Share Abstract Net share-based compensation expense, per common share: Share Based Compensation Expenses Basic and Diluted Per Share Basic and diluted (in dollars per share) The amount of share-based compensation expenses per each share of common stock or unit outstanding during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term of option Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate Forfeiture rate The forfeiture Rate assumption that is used in valuing an option on its own shares. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Type of Deferred Compensation [Axis] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Outstanding - Number of Options, Beginning Balance Outstanding - Number of Options, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross Granted - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period Exercised - Number of Options Issuance of common stock for options exercised (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Expirations In Period Expired - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Forfeited - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Number Vested and expected to vest - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Exercisable - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding - Weighted Average Exercise Price, Beginning balance Outstanding - Weighted Average Exercise Price, Ending Balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited - Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest - Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable - Weighted Average Exercise Price Plan Name [Axis] Plan Name [Domain] Long Term Incentive Plan2011 [Member] Range [Axis] Range [Domain] Maximum [Member] Minimum [Member] Title of Individual [Axis] Relationship to Entity [Domain] Equity Components [Axis] Equity Component [Domain] Award Type [Axis] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Allocated Share-based Compensation Expense Share Based Compensation Estimated Forfeiture Rate Represents the estimated rate of forfeiture. Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of Exercise Prices Lower Range Limit Income Tax Contingency [Table] Equity Award [Domain] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Unrecognized Tax Benefits, Beginning Balance Unrecognized Tax Benefits Unrecognized tax benefits balance at January 1 Unrecognized tax benefits balance at December 31 Statement Of Financial Position [Abstract] Statement [Table] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Prepaid Expense and Other Assets, Current Prepaid expenses and other Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net Other Assets, Noncurrent Other assets Assets, Total Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued liabilities Notes Payable, Noncurrent Note payable, net of discount Notes Payable, Current Note payable, net of discount Derivative Liability, Noncurrent Contingent rights derivative liability Preferred Stock, Value, Issued Convertible preferred stock, $1.00 par value; 5,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2016 and December 31, 2015 Common Stock, Value, Issued Common stock, $.01 par value: 170,000,000 shares authorized; 49,537,267 and 32,525,356 shares issued at September 30, 2016 and December 31, 2015, respectively Common Stock To Be Issued Common stock to be issued These lines are represents issuance of common stock. Additional Paid in Capital, Total Additional paid-in capital Treasury Stock, Value Treasury stock, at cost: 79,545 shares held Liabilities Total liabilities Preferred Stock, Par or Stated Value Per Share Convertible preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Convertible preferred stock, shares authorized Preferred Stock, Shares Issued Convertible preferred stock, shares issued Preferred Stock, Shares Outstanding Convertible preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Income Statement [Abstract] Revenues [Abstract] Revenues: Costs and Expenses [Abstract] Costs and expenses: Cost of Goods Sold Cost of product sales Research and Development Expense, Total Research and development General and Administrative Expense, Total General and administrative Interest Income (Expense), Net Interest expense, net Increase (Decrease) in Derivative Liabilities Change in fair value of contingent rights Net Income (Loss) Attributable to Parent, Total Net loss Net loss Earnings Per Share, Basic and Diluted, Total Net loss per share (basic and diluted) Statement Of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Net gain on disposal of assets Increase (Decrease) In Accounts Receivable Accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Accrued Liabilities, Total Accrued liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from Sale of Property, Plant, and Equipment, Total Proceeds from sale of furniture and equipment Payments to Acquire Property, Plant, and Equipment, Total Purchases of furniture and equipment Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Cash and Cash Equivalents, Period Increase (Decrease), Total Net increase (decrease) in cash and cash equivalents Basis Of Accounting [Text Block] Basis of Accounting [Text Block] Commitments and Contingencies Commitments and contingencies New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Research and Development [Abstract] Research, Development, and Computer Software Disclosure [Text Block] Schedule Of License Arrangements and Acquisition of In Process Research and Development [Table] A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Related Party [Axis] Related Party [Domain] Spectrum Pharmaceuticals [Member] Business Acquisition [Axis] Contingent Consideration Fair Value Of License Represents the amount recorded for contingent purchase rights at their estimated fair values based on the fair value of the consideration exchanged. Stock Issued During Period, Shares, Acquisitions Debt Instrument, Interest Rate, Stated Percentage Finite-Lived Intangible Assets by Major Class [Axis] Business Acquisition, Acquiree [Domain] Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Liabilities - Contingent Rights December 31, 2015 Balance at September 30, 2016 Debt Disclosure [Abstract] Debt Disclosure [Text Block] Schedule of Notes payable [Table] Subsequent Event Type [Axis] Amortization of Debt Discount (Premium) Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Partial settlement of Contingent Rights Partial settlement of contingent rights derivative Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total Change in fair value of Contingent Rights Stockholders Equity Attributable To Parent [Abstract] Stockholders’ equity (deficit): Liabilities and Equity, Total Total liabilities and stockholders’ equity (deficit) Weighted Average Number Of Shares Outstanding, Basic and Diluted Weighted average number of common shares outstanding (basic and diluted) Paid-in-Kind Interest Non-cash interest Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Share Based Compensation Arrangement By Share Based Payment Award Options Granted Subject To Achievement Gross number of share options (or share units) of common stock to be available for grants and awards issuance subject to achievement. Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Range of Exercise Prices Upper Range Limit Debt Instrument, Maturity Date, Description Percentage Of Ownership Interest In Non Stock Subsidiary Percentage of ownership interest held by the parent entity in the non stock subsidiary. Assets, Current, Total Total current assets Treasury Stock, Shares Treasury stock, shares held Costs and Expenses, Total Costs and expenses Revenue, Net Product sales Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Stock Issued [Domain] Geographical [Axis] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash financing activity: Liabilities, Current, Total Total current liabilities Crown Biosciences, Inc [Member] Related Party Transaction, Amounts of Transaction Contingent Rights Aggregate Amount It represents Contingent Rights Aggregate Amount Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Sale of Stock [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Contingent Rights Expiration Describes the terms of contingent rights expiration and it's possible extension. Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Maximum Stock To Be Issued Maximum stock to be issued. Investors [Member] Securities Purchase Agreements [Abstract] Shares Issued, Price Per Share Percentage of Warrant Coverage On Purchase Price Percentage of warrant coverage on purchase price. EX-101.PRE 11 casi-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2016	Nov. 07, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Entity Registrant Name	CASI Pharmaceuticals, Inc.
Entity Central Index Key	0000895051
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CASI
Entity Common Stock, Shares Outstanding		60,196,574

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 24,137,329	$ 5,131,114
Prepaid expenses and other	401,080	438,231
Total current assets	24,538,409	5,569,345
Property and equipment, net	184,090	218,796
Other assets	34,485	38,174
Total assets	24,756,984	5,826,315
Current liabilities:
Accounts payable	918,892	884,100
Accrued liabilities	161,978	169,464
Note payable, net of discount	1,485,985	0
Total current liabilities	2,566,855	1,053,564
Note payable, net of discount	0	1,464,970
Contingent rights derivative liability	6,167,142	9,395,222
Total liabilities	8,733,997	11,913,756
Commitments and contingencies
Stockholders’ equity (deficit):
Convertible preferred stock, $1.00 par value; 5,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2016 and December 31, 2015	0	0
Common stock, $.01 par value: 170,000,000 shares authorized; 49,537,267 and 32,525,356 shares issued at September 30, 2016 and December 31, 2015, respectively	495,371	325,252
Common stock to be issued	6,274,000	0
Additional paid-in capital	456,545,927	434,099,890
Treasury stock, at cost: 79,545 shares held	(8,034,244)	(8,034,244)
Accumulated deficit	(439,258,067)	(432,478,339)
Total stockholders’ equity (deficit)	16,022,987	(6,087,441)
Total liabilities and stockholders’ equity (deficit)	$ 24,756,984	$ 5,826,315

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets [Parenthetical] - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Convertible preferred stock, par value (in dollars per share)	$ 1.00	$ 1.00
Convertible preferred stock, shares authorized	5,000,000	5,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	49,537,267	32,525,356
Treasury stock, shares held	79,545	79,545

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Product sales	$ 0	$ 0	$ 0	$ 47,712
Costs and expenses:
Cost of product sales	0	0	0	6,274
Research and development	1,013,929	942,338	3,395,362	3,030,648
General and administrative	676,927	673,910	3,356,804	2,459,024
Costs and expenses	1,690,856	1,616,248	6,752,166	5,495,946
Interest expense, net	5,614	24,346	23,140	72,836
Change in fair value of contingent rights	(2,978)	(35,690)	4,422	(17,346)
Net loss	$ (1,693,492)	$ (1,604,904)	$ (6,779,728)	$ (5,503,724)
Net loss per share (basic and diluted)	$ (0.03)	$ (0.05)	$ (0.15)	$ (0.17)
Weighted average number of common shares outstanding (basic and diluted)	49,227,983	32,445,811	44,132,599	32,445,811

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (6,779,728)	$ (5,503,724)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	47,963	50,771
Net gain on disposal of assets	(12,461)	0
Stock-based compensation expense	2,201,401	1,193,419
Non-cash interest	21,015	67,950
Change in fair value of contingent rights	4,422	(17,346)
Changes in operating assets and liabilities:
Accounts receivable	0	23,727
Prepaid expenses and other	40,840	(88,997)
Accounts payable	34,793	46,645
Accrued liabilities	(7,486)	5,285
Net cash used in operating activities	(4,449,241)	(4,222,270)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of furniture and equipment	158,446	0
Purchases of furniture and equipment	(159,244)	(23,729)
Net cash used in investing activities	(798)	(23,729)
CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuance costs	(72,087)	0
Proceeds from sale of common stock	17,254,341
Proceeds from sale of common stock to be issued	6,274,000	0
Net cash provided by financing activities	23,456,254	0
Net increase (decrease) in cash and cash equivalents	19,006,215	(4,245,999)
Cash and cash equivalents at beginning of period	5,131,114	10,669,919
Cash and cash equivalents at end of period	24,137,329	6,423,920
Non-cash financing activity:
Partial settlement of contingent rights derivative	$ 3,232,502	$ 0

XML 17 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Accounting [Text Block]

Basis of Presentation

Liquidity Risks and Management’s Plans

XML 18 R7.htm IDEA: XBRL DOCUMENT

License Arrangements and Acquisition of In-Process Research and Development

9 Months Ended

Sep. 30, 2016

Research and Development [Abstract]

Research, Development, and Computer Software Disclosure [Text Block]

License Arrangements and Acquisition of In-Process Research and Development

MARQIBO^® (vinCRIStine sulfate LIPOSOME injection) (“Marqibo”);

ZEVALIN^® (ibritumomab tiuxetan) (“Zevalin”); and

EVOMELA^® (melphalan) for Injection (“Evomela”).

The Company is in various stages of the regulatory and development process to obtain marketing approval for MARQIBO^®, ZEVALIN^® and EVOMELA^® in its territorial region, with ZEVALIN^® commercially available in Hong Kong. In January 2016, the China Food and Drug Administration (CFDA) accepted for review the Company’s import drug registration application for MARQIBO^® and currently is in the quality testing phase of the regulatory review. On March 10, 2016, Spectrum received notification from the U.S. Food and Drug Administration (FDA) of the grant of approval of its New Drug Application (NDA) for EVOMELA^® primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. The Company is working with its partner to finalize the CFDA submission for EVOMELA^® and expects to file by the end of 2016.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note Payable

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

Note Payable

XML 20 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

Fair Value Measurements

Level 1, defined as observable inputs such as quoted prices in active markets for identical assets;

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:

	As of September 30, 2016
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	6,167,142	$	6,167,142

	As of December 31, 2015
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	9,395,222	$	9,395,222

The following table presents the changes in the Company’s financial liabilities accounted for at fair value on a recurring basis using Level 3 unobservable inputs:

December 31, 2015	$	9,395,222
Partial settlement of Contingent Rights		(3,232,502)
Change in fair value of Contingent Rights		4,422
Balance at September 30, 2016	$	6,167,142

Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:

Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:

The Company does not have any non-financial assets and liabilities that are measured at fair value on a recurring basis.

Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2016

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Stockholders’ Equity

Securities Purchase Agreements

The offering closed after satisfaction of certain regulatory and customary closing conditions, with the net proceeds subject to payment of offering expenses, including fees and expenses.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

6.	Share-Based Compensation

	NINE MONTH PERIOD ENDED
	SEPTEMBER 30,
	2016		2015
Research and development	$	578,626	$	569,791
General and administrative		1,622,775		623,628
Share-based compensation expense	$	2,201,401	$	1,193,419
Net share-based compensation expense, per common share:
Basic and diluted	$	0.05	$	0.04

Following are the weighted-average assumptions used in valuing the stock options granted during the nine-month periods ended September 30, 2016 and 2015:

	NINE MONTH PERIOD ENDED
	SEPTEMBER 30,
	2016			2015
Expected volatility		83.03	%		85.28	%
Risk-free interest rate		1.31	%		1.58	%
Expected term of option		5.41 years			5.67 years
Forfeiture rate*		3.00	%		3.00	%
Expected dividend yield		0.00	%		0.00	%

The weighted average fair value of stock options granted during the nine-month periods ended September 30, 2016 and 2015 were $0.75 and $1.02, respectively.

A summary of the Company’s stock option plans and of changes in options outstanding under the plans for the nine months ended September 30, 2016 is as follows:

			Weighted
			Average
	Number of		Exercise
	Options		Price
Outstanding at January 1, 2016		6,694,744	$	1.99
Granted		3,336,357	$	0.95
Exercised		-	$	-
Expired		(836,062)	$	2.20
Forfeited		(127,795)	$	1.33
Outstanding at September 30, 2016		9,067,244	$	1.60
Vested and expected to vest at September 30, 2016		8,968,117	$	1.61
Exercisable at September 30, 2016		5,763,002	$	1.90

There were no option exercises during the three or nine months ended September 30, 2016 or 2015.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2016

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

Income Taxes

XML 24 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2016

Related Party Transactions

XML 25 R14.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements

9 Months Ended

Sep. 30, 2016

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

New Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact the Company’s condensed consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

	As of September 30, 2016
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	6,167,142	$	6,167,142

	As of December 31, 2015
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	9,395,222	$	9,395,222

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table presents the changes in the Company’s financial liabilities accounted for at fair value on a recurring basis using Level 3 unobservable inputs:

December 31, 2015	$	9,395,222
Partial settlement of Contingent Rights		(3,232,502)
Change in fair value of Contingent Rights		4,422
Balance at September 30, 2016	$	6,167,142

XML 27 R16.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense,as follows:

	NINE MONTH PERIOD ENDED
	SEPTEMBER 30,
	2016		2015
Research and development	$	578,626	$	569,791
General and administrative		1,622,775		623,628
Share-based compensation expense	$	2,201,401	$	1,193,419
Net share-based compensation expense, per common share:
Basic and diluted	$	0.05	$	0.04

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Following are the weighted-average assumptions used in valuing the stock options granted during the nine-month periods ended September 30, 2016 and 2015:

	NINE MONTH PERIOD ENDED
	SEPTEMBER 30,
	2016			2015
Expected volatility		83.03	%		85.28	%
Risk-free interest rate		1.31	%		1.58	%
Expected term of option		5.41 years			5.67 years
Forfeiture rate*		3.00	%		3.00	%
Expected dividend yield		0.00	%		0.00	%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the Company’s stock option plans and of changes in options outstanding under the plans for the nine months ended September 30, 2016 is as follows:

			Weighted
			Average
	Number of		Exercise
	Options		Price
Outstanding at January 1, 2016		6,694,744	$	1.99
Granted		3,336,357	$	0.95
Exercised		-	$	-
Expired		(836,062)	$	2.20
Forfeited		(127,795)	$	1.33
Outstanding at September 30, 2016		9,067,244	$	1.60
Vested and expected to vest at September 30, 2016		8,968,117	$	1.61
Exercisable at September 30, 2016		5,763,002	$	1.90

XML 28 R17.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details Textual) - USD ($)				1 Months Ended		9 Months Ended
Basis of Presentation (Details Textual) - USD ($)	Oct. 03, 2016	Jul. 05, 2016	Jan. 15, 2016	Oct. 24, 2016	Jun. 24, 2016	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015
Description of Business and Basis of Presentation [Line Items]
Retained Earnings (Accumulated Deficit), Total						$ (439,258,067)	$ (432,478,339)
Percentage Of Ownership Interest In Non Stock Subsidiary						100.00%
Proceeds from Issuance of Common Stock						$ 17,254,341
CASI China [Member]
Description of Business and Basis of Presentation [Line Items]
Cash						$ 6,200,000
First Closing [Member]
Description of Business and Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock And Warrants			$ 10,200,000
Proceeds from Issuance of Common Stock			$ 10,300,000
Second Closing [Member]
Description of Business and Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock And Warrants					$ 6,000,000
Third Closing [Member]
Description of Business and Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock And Warrants		$ 1,000,000
Subsequent Event [Member]
Description of Business and Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock And Warrants				$ 3,000,000
Subsequent Event [Member] \| Final Closing [Member]
Description of Business and Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock And Warrants	$ 7,800,000
Investors [Member]
Description of Business and Basis of Presentation [Line Items]
Maximum Stock To Be Issued								$ 25,100,000

XML 29 R18.htm IDEA: XBRL DOCUMENT

License Arrangements and Acquisition of In-Process Research and Development (Details Textual) - USD ($)	1 Months Ended			9 Months Ended		12 Months Ended
	Oct. 31, 2016	Jul. 31, 2016	Feb. 29, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2015
License Arrangements and Acquisition of In Process Research and Development [Line Items]
Liabilities - Contingent Rights				$ 6,167,142			$ 9,395,222
Notes Payable, Noncurrent				0			$ 1,464,970
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements				$ 3,232,502	$ 0
Contingent Rights [Member]
License Arrangements and Acquisition of In Process Research and Development [Line Items]
Debt Instrument, Maturity Date, Description				March 2017
Spectrum [Member]
License Arrangements and Acquisition of In Process Research and Development [Line Items]
Stock Issued During Period, Shares, New Issues			1,688,877
Spectrum [Member] \| Second Closing [Member]
License Arrangements and Acquisition of In Process Research and Development [Line Items]
Stock Issued During Period, Shares, New Issues		980,732
Spectrum [Member] \| Third Closing [Member]
License Arrangements and Acquisition of In Process Research and Development [Line Items]
Stock Issued During Period, Shares, New Issues		164,526
Spectrum [Member] \| Fisrt, Second And Third Closing [Member]
License Arrangements and Acquisition of In Process Research and Development [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements				$ 3,232,502
Spectrum [Member] \| Final Closing [Member] \| Subsequent Event [Member]
License Arrangements and Acquisition of In Process Research and Development [Line Items]
Stock Issued During Period, Shares, New Issues	1,789,062
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	$ 2,047,243
Spectrum Pharmaceuticals [Member]
License Arrangements and Acquisition of In Process Research and Development [Line Items]
Contingent Consideration Fair Value Of License						$ 19,700,000
Stock Issued During Period, Shares, Acquisitions						5,405,382
Debt Instrument, Interest Rate, Stated Percentage						0.50%
Notes Payable, Noncurrent						$ 1,500,000
Contingent Rights Aggregate Amount				$ 50,000,000
Contingent Rights Expiration				These Contingent Rights will expire on the earlier of raising an aggregate of $50 million or September 17, 2019 (subject to possible extension only for certain outstanding derivative securities).

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note Payable (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
Note Payable (Details Textual) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2014
Notes Payable [Line Items]
Amortization of Debt Discount (Premium)	$ 21,015	$ 67,950
Spectrum Pharmaceuticals [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			0.50%
Debt Instrument Initial Discount Upon Issuance			$ 136,000
Debt Instrument, Face Amount			$ 1,500,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities - Contingent Rights	$ 6,167,142	$ 9,395,222
Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities - Contingent Rights	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities - Contingent Rights	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities - Contingent Rights	$ 6,167,142	$ 9,395,222

XML 32 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details 1) - USD ($)	9 Months Ended
Fair Value Measurements (Details 1) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
December 31, 2015	$ 9,395,222
Partial settlement of Contingent Rights	(3,232,502)	$ 0
Change in fair value of Contingent Rights	4,422
Balance at September 30, 2016	$ 6,167,142

XML 33 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual) - USD ($)				1 Months Ended			9 Months Ended
Stockholders' Equity (Details Textual) - USD ($)	Oct. 03, 2016	Jul. 05, 2016	Jan. 15, 2016	Oct. 24, 2016	Jun. 24, 2016	Sep. 20, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Proceeds from Issuance of Common Stock							$ 17,254,341
Common Stock, Shares, Issued							49,537,267		32,525,356
Proceeds From Sale of Common Stock To Be Issued							$ 6,274,000	$ 0
Investors [Member]
Percentage of Warrant Coverage On Purchase Price						20.00%
Warrants Purchase Price Per share						$ 0.125
Class of Warrant or Right, Exercise Price of Warrants or Rights						1.69
Shares To Be Issued Per Share						$ 1.19
Warrants To Be Issued						4,131,686
Stock And Warrants To Be Issued Value						$ 25,100,000
Common Stock To Be Issued						20,658,434
Subsequent Event [Member]
Shares Issued, Price Per Share				$ 1.190
Percentage of Warrant Coverage On Purchase Price				20.00%
Warrants Purchase Price Per share				$ 0.125
Class Of Warrant Or Right Maturity Period Description				The warrants will become exercisable on January 23, 2017 at $1.69 per share exercise price, and will expire on January 23, 2020.
Fair Value Of Warrant Issued				$ 306,173
Fair Value Assumptions Fair Value				$ 0.62
Fair Value Assumptions, Expected Term				3 years 3 months
Fair Value Assumptions, Risk Free Interest Rate				1.00%
Fair Value Assumptions, Expected Volatility Rate				72.20%
Warrants Issued				493,827
Common Stock, Shares, Issued				2,469,135
Proceeds from Issuance of Common Stock And Warrants				$ 3,000,000
First Closing [Member]
Warrants Purchase Price Per share			$ 0.125
Class Of Warrant Or Right Maturity Period Description			The warrants became exercisable on April 15, 2016 at $1.69 per share exercise price, and will expire on April 15, 2019.
Fair Value Of Warrant Issued			$ 321,047
Fair Value Assumptions Fair Value			$ 0.19
Fair Value Assumptions, Expected Term			3 years 3 months
Fair Value Assumptions, Risk Free Interest Rate			1.08%
Fair Value Assumptions, Expected Volatility Rate			70.10%
Warrants Issued			1,689,722
Proceeds from Issuance of Common Stock			$ 10,300,000
Sale of Stock, Number of Shares Issued in Transaction			8,448,613
Sale of Stock, Price Per Share			$ 1.19
Proceeds from Issuance of Common Stock And Warrants			$ 10,200,000
Second Closing [Member]
Warrants Purchase Price Per share					$ 0.125
Class Of Warrant Or Right Maturity Period Description					The warrants became exercisable on September 23, 2016 at $1.69 per share exercise price, and will expire on September 23, 2019.
Fair Value Of Warrant Issued					$ 431,738
Fair Value Assumptions Fair Value					$ 0.44
Fair Value Assumptions, Expected Term					3 years 3 months
Fair Value Assumptions, Risk Free Interest Rate					0.76%
Fair Value Assumptions, Expected Volatility Rate					70.40%
Warrants Issued					981,223
Sale of Stock, Number of Shares Issued in Transaction					4,906,118
Sale of Stock, Price Per Share					$ 1.19
Proceeds from Issuance of Common Stock And Warrants					$ 6,000,000
Third Closing [Member]
Warrants Purchase Price Per share		$ 0.125
Class Of Warrant Or Right Maturity Period Description		The warrants became exercisable on October 4, 2016 at $1.69 per share exercise price, and will expire on October 4, 2019.
Fair Value Of Warrant Issued		$ 67,490
Fair Value Assumptions Fair Value		$ 0.41
Fair Value Assumptions, Expected Term		3 years 3 months
Fair Value Assumptions, Risk Free Interest Rate		0.66%
Fair Value Assumptions, Expected Volatility Rate		70.60%
Warrants Issued		164,609
Sale of Stock, Number of Shares Issued in Transaction		823,045
Sale of Stock, Price Per Share		$ 1.19
Proceeds from Issuance of Common Stock And Warrants		$ 1,000,000
Final Closing [Member]
Proceeds From Sale of Common Stock To Be Issued							$ 6,300,000
Final Closing [Member] \| Subsequent Event [Member]
Warrants Purchase Price Per share	$ 0.125
Class Of Warrant Or Right Maturity Period Description	The warrants will become exercisable on January 2, 2017 at $1.69 per share exercise price, and will expire on January 2, 2020.
Fair Value Of Warrant Issued	$ 544,374
Fair Value Assumptions Fair Value	$ 0.42
Fair Value Assumptions, Expected Term	3 years 3 months
Fair Value Assumptions, Risk Free Interest Rate	0.91%
Fair Value Assumptions, Expected Volatility Rate	71.40%
Warrants Issued	1,296,129
Sale of Stock, Number of Shares Issued in Transaction	6,480,655
Sale of Stock, Price Per Share	$ 1.19
Proceeds from Issuance of Common Stock And Warrants	$ 7,800,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details) - USD ($)	9 Months Ended
Share-Based Compensation (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 2,201,401	$ 1,193,419
Net share-based compensation expense, per common share:
Basic and diluted (in dollars per share)	$ 0.05	$ 0.04
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 578,626	$ 569,791
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,622,775	$ 623,628

XML 35 R24.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details 1)

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected volatility

83.03%

85.28%

Risk-free interest rate

1.31%

1.58%

Expected term of option

5 years 4 months 28 days

5 years 8 months 1 day

Forfeiture rate

^[1]

3.00%

Expected dividend yield

0.00%

[1]	Authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the nine-month periods ended September 30, 2016 and 2015, forfeitures were estimated at 3%.

XML 36 R25.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details 2)	9 Months Ended
Share-Based Compensation (Details 2)	Sep. 30, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding - Number of Options, Beginning Balance \| shares	6,694,744
Granted - Number of Options \| shares	3,336,357
Exercised - Number of Options \| shares	0
Expired - Number of Options \| shares	(836,062)
Forfeited - Number of Options \| shares	(127,795)
Outstanding - Number of Options, Ending Balance \| shares	9,067,244
Vested and expected to vest - Number of Options \| shares	8,968,117
Exercisable - Number of Options \| shares	5,763,002
Outstanding - Weighted Average Exercise Price, Beginning balance \| $ / shares	$ 1.99
Granted - Weighted Average Exercise Price \| $ / shares	0.95
Exercised - Weighted Average Exercise Price \| $ / shares	0
Expired - Weighted Average Exercise Price \| $ / shares	2.2
Forfeited - Weighted Average Exercise Price \| $ / shares	1.33
Outstanding - Weighted Average Exercise Price, Ending Balance \| $ / shares	1.6
Vested and expected to vest - Weighted Average Exercise Price \| $ / shares	1.61
Exercisable - Weighted Average Exercise Price \| $ / shares	$ 1.9

XML 37 R26.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details Textual) - USD ($)	9 Months Ended
Share-Based Compensation (Details Textual) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.75	$ 1.02
Share-based Compensation, Total	$ 2,201,401	$ 1,193,419
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	9,067,244			6,694,744
Share Based Compensation Estimated Forfeiture Rate	3.00%	3.00%
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 10,100
Certain Board Members Officers And Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Granted Subject To Achievement	873,000
Long Term Incentive Plan2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	2,554,019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	9,067,244
Long Term Incentive Plan2011 [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			11,230,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 17.38
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Long Term Incentive Plan2011 [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			8,230,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 0.86
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year

XML 38 R27.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Textual) $ in Millions	Dec. 31, 2015 USD ($)
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits	$ 3.1

XML 39 R28.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Research and Development Expense, Total	$ 1,013,929	$ 942,338	$ 3,395,362	$ 3,030,648
Crown Biosciences, Inc [Member]
Related Party Transaction, Amounts of Transaction			66,545
Research and Development Expense, Total			28,648	24,750
Due to Related Parties, Current	$ 16,648		16,648
Spectrum [Member]
Research and Development Expense, Total			$ 133,770
Investors [Member]
Maximum Stock To Be Issued		$ 25,100,000		$ 25,100,000

EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

AGEF23Q)82/A#D?K*'RT U4(.*!P^-[## M"@UT"X+,08SQ8IF#IN,E&2_'>+F,#RSFD\2,DGJ4K+4QUD 6Y$((E6+"@*0= M*=*1PAD9.EZ3\1IG%!C-)XE>&)7&:A&D@U6*&1,9?T-Z,=B+#;P8U,J:@]0\ M,(-EC#:2D48R9"1C@9$,M0# N&2A$ZSCW K)+>W'DGXL]A.TDUOLAS,>3- = M5FEC5:1O!JA1'&!XF$(WL^;3,R,AG,V$:LV-D)$IR2- MD*$AB5H2GA$A(@B9U%JJB!\:>%QA/^@]I'#F1F8Z](-E"K*8'9J?' ,T0]V# MV;B64EJ0(2U()?B?B)?OF5O?#WF]1^O@8\ +#AC8HS_G3;MK2?U2SW5R+D_NK M:$^7NDM>F]YOE\=-[;%I>N<=LB]^QIQ=<7A* MQ\>2[?]02P,$% @ 0U!N28V1B+J? 0 L , !@ !X;"]W;W)KO&EEW)%VWO<'QES5@1;N#GLP MX:9!JX4/IFV9ZRV(.H&T8CS+/C$MI*%ED7S/MBQP\$H:>+;$#5H+^_<$"LG5\2+;SD<'*PNVX&JIP3B)AEAHCO0Q/YSV,2(%_)(PNM691.UGQ-=H_*B/ M-(L20$'E(X,(VP6>0*E(%!+_F3G?4T;@^GQE_Y:J#>K/PL$3JM^R]ET0FU%2 M0R,&Y5]P_ YS"?>1L$+ETDJJP7G45P@E6KQ-NS1I'Z>;+]D,VP;P&$NN"]E \/!;M$GCGD-(7P54B^ M1+! OF3@6QE._#\XWX;O-@7N$GRWSIYEVP3[38)](MA_(,AO2MR*N57)5BW5 M8-LT.8Y4.)@TIROO,IR//#W)>WA9]**%G\*VTCAR1A\>-K6_0?00I&1W]Y1T MX?LLAH+&Q^/G<+;31$V&Q_[Z/Y9/6OX#4$L#!!0 ( $-0;DDI'!HYH0$ M +$# 8 >&PO=V]R:W-H965T&UL;5/!;N,@$/T5Y \H M#G'2*G(L-5U5[6&EJH?=,[''-BHP+N"X^_<%[+ANUQ=@AGEOW@Q#/J!YLRV M(Q]*:GM,6N>Z Z6V;$%Q>X,=:']3HU'<>=,TU'8&>!5!2E*6IGNJN-!)D4?? MBRER[)T4&EX,L;U2W/P[@<3AF&R2J^-5-*T+#EKD=,950H&V C4Q4!^3^\WA ME(6(&/!'P& 79Q*TGQ'?@O%<'9,T2 )I0L,W&\7> I Y%/_#YQ?J4,P.7Y MROX8J_7JS]S" \J_HG*M%YLFI(*:]]*]XO $4PF[0%BBM'$E96\=JBLD(8I_ MC+O0<1_&F]O]!%L'L G 9L!=&H6/B:+,7]SQ(CL M.]YYH=9[+\4FW>;T$HBFF-,8PY8Q*C!-'!U+2NQU'-2%=Y[.>Q;?Y"N\R#O> MP&]N&J$M.:/S+QO[7R,Z\%+2FUU"6O]_9D-"[<+QUI_-.%*CX;"[?I#YEQ:? M4$L#!!0 ( $-0;DFZSDLLH@$ +$# 8 >&PO=V]R:W-H965T&UL;5/!;MP@$/T5Q <$F]TTRO!F&8D3[ZCH 3]ZT,NY(.^_[ V.NZD +=X,]F'#3H-7" M!].VS/461)U 6C&>95^8%M+0LDB^9UL6.'@E#3Q;X@:MA?U[ H7CD>;TZGB1 M;>>C@Y4%6W"UU&"<1$,L-$?ZF!].^QB1 GY)&-WJ3*+V,^)K-'[41YI%":"@ M\I%!A.T"3Z!4) J)_\R<[RDC<'V^LG]+U0;U9^'@"=5O6?LNB,THJ:$1@_(O M.'Z'N83;2%BA \ZBN$$BW>IEV:M(_3#7^88=L /@/X KC/DO I49+Y M57A1%A9'8J?6]B*^8'[@H1%5=*:ZTUT0ZH+W4N;97<$ND6B..4TQ?!VS1+# MOJ3@6RE._#\XWX;O-A7N$GSW0>']-L%^DV"?"/8?"!X^E;@1DV>?DK!53S78 M-HV.(Q4.)@WJRKM,YR-/;_(>7A:]:.&GL*TTCIS1AY=-_6\0/00IV!?.=AJIR?#87S_(\DO+?U!+ P04 " !#4&Y)\%CU5*$! "Q M P & 'AL+W=O!0>K2K;B&J% 6X&:&&B/]#X]G(H0 M$0-^"9CLYDR"]C/B2S!^-$>:! D@H7:!@?OM @\@92#RB5\7SO>4 ;@]7]F_ MQ6J]^C.W\(#RMVA<[\4FE#30\E&Z9YR^PU+";2"L4=JXDGJT#M450HGB;_,N M=-RG^2:_6V#[@&P!9"O@:Q*%SXFBS$?N>%4:G(B96SOP\(+I(?.-J(,SUAWO MO%#KO9%_R$H M=@F*2%!\(,@_E;@74WQ*PC8]56"Z.#J6U#CJ.*@;[SJ=]UE\D_?PJAQX!S^Y MZ82VY(S.OVSL?XOHP$M);FXIZ?W_60T)K0O'+_YLYI&:#8?#]8.LO[3Z"U!+ M P04 " !#4&Y)ED7:BJ$! "Q P &0 'AL+W=OT5=J#]38U&<>=- MTS#;&>!5!"G)LB2Y9HH+38L\^EY-D6/OI-#P:HCME>+FWQ$D#@>:THOC332M M"PY6Y&S&54*!M@(U,5 ?Z%VZ/VY#1 SX(V"PBS,)VD^([\%XK@XT"1) 0ND" M _?;&>Y!RD#D$W],G%\I W!YOK _QFJ]^A.W<(_RKZA M8"IA%PA+E#:NI.RM0W6!4*+XY[@+'?=AO-DE$VP=D$V ; ;<1@ ;$T69#]SQ M(CL.]YYH=9[ST6:[G)V#D13S'&,R98Q ,OW#1"6W)"YU\V]K]&=."E)%<[2EK_?V9# M0NW"\<:?S3A2H^&PNWR0^9<6_P%02P,$% @ 0U!N206# XFA 0 L0, M !D !X;"]W;W)K&UL;5/!;MP@$/T5Q <$F]TD M[O!F&8D3[ZCH 3]ZU M,NY(.^_[ V.NZD +=X,]F'#3H-7"!].VS/461)U 6C&>97=,"VEH623?LRT+ M'+R2!IXM<8/6POXY@<+Q2'-Z=;S(MO/1P-T5;-53#;9-H^-(A8-)@[KR+M/YP-.;?(2712]:^"EL M*XTC9_3A95/_&T0/04IVA[.=1FHR//;7#[+\TO(O4$L# M!!0 ( $-0;DE>R^[SH $ +$# 9 >&PO=V]R:W-H965TE-3VF'3.]0=*;=6!XO8&>]#^ID&CN/.F M::GM#? Z@I2D+$UOJ>)")V41?<^F+'!P4FAX-L0.2G'S_P02QV.R2V;'BV@[ M%QRT+.B"JX4";05J8J Y)O>[PRD/$3'@CX#1KLXD:#\CO@;C5WU,TB !)%0N M,'"_7> !I Q$/O&_*^='R@!>REW+"OH)1!=8TY3#%O'+!'4LR\I MV%:*$_L&9]OP;%-A%N'9)X7Y-D&^29!'@OP3P?Y+B5LQMU^2T%5/%9@VCHXE M%0XZ#NK*NTSG/8MO\A%>%CUOX3"GIS3XAG?\_BR&A M<>'XPY_--%*3X;"?/\CR2\MW4$L#!!0 ( $-0;DFSM+(YH@$ +$# 9 M >&PO=V]R:W-H965T;,-@",?6K7V M0!OGNCUCMFA "WN%';3^ID*CA?.FJ9GM#(@R@K1B/$FNF1:RI7D6?2\FS[!W M2K;P8HCMM1;FWQ$4#@>:THOC5=:-"PZ69VS&E5)#:R6VQ$!UH'?I_K@-$3'@ MCX3!+LXD:#\AO@7CN3S0)$@ !84+#,)O9[@'I0*13_P^<7ZF#,#E^<+^&*OU MZD_"PCVJO[)TC1>;4%)")7KE7G%X@JF$72 L4-FXDJ*W#O4%0HD6'^,NV[@/ MX\TNG6#K #X!^ RX3:+P,5&4^2" M>\Y3?I.Q 0 L0, !D !X;"]W;W)K&UL=5/;;MP@$/T5Q <$W])6*Z^E;*JJ?:@4Y:%]9NVQC0*,"WB=_GT! M>QUGX[X ,\PY:5F7T/9FJQ-%)H>')$#LJQSZ'H7 M'*PJV8IKA )M!6IBH#W2A_1P*D)$#/@E8+*;,PG:SX@OP?C1'&D2)("$V@4& M[K<+/(*4@<@G_K-POJ4,P.WYROXM5NO5G[F%1Y2_1>-Z+S:AI(&6C](]X_0= MEA+N V&-TL:5U*-UJ*X02A1_G7>AXS[--U^2!;8/R!9 =@-@,'TD/E&U,$9ZXYW7JCUWDN5YFG)+H%HB3G-,=DV9HU@GGU-D>VE M.&4?X-D^/-]5F$=X_D[A?PB*78(B$A3O"/*;$O=BBILD;--3!::+HV-)C:.. M@[KQKM/YD,4W>0NORH%W\).;3FA+SNC\R\;^MX@.O)3D[IZ2WO^?U9#0NG#\ M[,]F'JG9<#A&PO=V]R:W-H965T0'*+:3M%WD6&HZ M3>W%I*H7W36QCVU4X'B X^[M"]AQO8S=!#A\?\= BA'UN^D +/F00IE#TEG; M[RDU50>2F1OL0;F=!K5DUBUU2TVO@=6!) 7-T_262L954A:A]J++ @]9\\O2$]?SB_J/T*U+?V(& M'E'\XK7M7-@T(34T;!#V%<PZJZ/(&'/!S\%[PL M>M;"3Z9;K@PYH777)QQR@VC!14EO7);./=)E(:"Q?GKGYGJZM]/"8G]YA&PO=V]R:W-H965T M(#+,HXMIDX)CO;-.U%D\U>M->,'I4L M/Q9PW+Y] 1W7M?1&X/#]G(,^@"N2KSR&B9 &J8DTM">D\?L="D\(@!^,IC,9HY\[E>E7OWB>W-. M4I\"<*BM5Z!NN,$3<.Z%G/'O1?/=TA.W\[OZUU"MR_Y*#3PI_HLUMG?)I@EJ MH*4CMR]J^@9+"4C':C_@]F)N(.H?3#4'?9:$%!_$.)V:[$&.8_61ZC)L>( MP&%G$L/D<9,B:E)$!(X[DQBFV)G@S>T0H+O0! ;5:I2AY3;1M<\>2;A=[_"J M'&@'/ZCNF#3HJJR[H^$FM4I9<*FD#Z[@WKT$ZX)#:_WTDYOKN3GFA57#O=77 M]Z;Z"U!+ P04 " !#4&Y).+VB0O<" ".#0 &0 'AL+W=OGLP^YSJE&9 M G$AUNZ_WR1$*W!QT0[X10WF>1E_74WRFUOP^">K43 M!:_OY%Z4^LE&5@57NEEM@WI?";ZVI"(/59*5XK MKSX4!:_^/HA<'J<^\D\=/[/M3IF.8#8)SKQU5HBRSF3I56(S];^C^R6.#<0B M?F7B6%_<>Z;X-RG?36.YGOJAJ4'D8J5,"*XO'V(N\MQ$TIG_N*!?.0WQ\OX4 M_=G*U>6_\5K,9?X[6ZN=KC;TO;78\$.N?LKCBW :(A-P)?/:_GNK0ZUD<:+X M7L$_FVM6VNNQ><*(H\$$[ CX3$#T*H$X AE+H(Y QQ(B1XC&$I@CL+&$V!'B ML83$$9*QA-01T@XA:.;/SOXC5WPVJ>31JYI7=L^-,]!]JM^OE>FTKY-]IN>_ MUKT?,T3C2?!A CG,0X/!+4S2QLPA3-K&/ *8*&QCGB ,:F.>(0QN8Q9]3 ?Q M B"B-F39A["O*($>U_/@8G!PL>635J$$#D# ,0&H*T M*.TP<064UK,-TI2 M'"4AZTSD"PC%-$X(2>&R*%@6!(P0#Q^'E.P )4$''/8NDIY7I+4O_X$0IF"CM)V(#

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

&UL4$L! A0# M% @ 0U!N2;.TLCFB 0 L0, !D ( !_C$ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 0U!N20HC M5CFY 0 >P0 !D ( !CS< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0U!N21+WK0DB @ =@8 !D M ( !=D 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 0U!N26! Y!P5!@ NR, !D ( ! M0T< 'AL+W=O ID0" ^!P &0 @ &/30 >&PO=V]R:W-H965T&UL4$L! A0#% M @ 0U!N25Z+B+&U @ WPD !D ( !?5( 'AL+W=O&PO XML 41 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 42 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 55 147 1 true 24 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.entremed.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.entremed.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] Sheet http://www.entremed.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets [Parenthetical] Statements 3 false false R4.htm 104 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.entremed.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 105 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.entremed.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 106 - Disclosure - Basis of Presentation Sheet http://www.entremed.com/role/BasisOfPresentation Basis of Presentation Notes 6 false false R7.htm 107 - Disclosure - License Arrangements and Acquisition of In-Process Research and Development Sheet http://www.entremed.com/role/LicenseArrangementsAndAcquisitionOfInprocessResearchAndDevelopment License Arrangements and Acquisition of In-Process Research and Development Notes 7 false false R8.htm 108 - Disclosure - Note Payable Sheet http://www.entremed.com/role/NotePayable Note Payable Notes 8 false false R9.htm 109 - Disclosure - Fair Value Measurements Sheet http://www.entremed.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 110 - Disclosure - Stockholders' Equity Sheet http://www.entremed.com/role/StockholdersEquity Stockholders' Equity Notes 10 false false R11.htm 111 - Disclosure - Share-Based Compensation Sheet http://www.entremed.com/role/SharebasedCompensation Share-Based Compensation Notes 11 false false R12.htm 112 - Disclosure - Income Taxes Sheet http://www.entremed.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 113 - Disclosure - Related Party Transactions Sheet http://www.entremed.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 114 - Disclosure - New Accounting Pronouncements Sheet http://www.entremed.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 14 false false R15.htm 115 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.entremed.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.entremed.com/role/FairValueMeasurements 15 false false R16.htm 116 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.entremed.com/role/SharebasedCompensationTables Share-Based Compensation (Tables) Tables http://www.entremed.com/role/SharebasedCompensation 16 false false R17.htm 117 - Disclosure - Basis of Presentation (Details Textual) Sheet http://www.entremed.com/role/BasisOfPresentationDetailsTextual Basis of Presentation (Details Textual) Details http://www.entremed.com/role/BasisOfPresentation 17 false false R18.htm 118 - Disclosure - License Arrangements and Acquisition of In-Process Research and Development (Details Textual) Sheet http://www.entremed.com/role/LicenseArrangementsAndAcquisitionOfInprocessResearchAndDevelopmentDetailsTextual License Arrangements and Acquisition of In-Process Research and Development (Details Textual) Details http://www.entremed.com/role/LicenseArrangementsAndAcquisitionOfInprocessResearchAndDevelopment 18 false false R19.htm 119 - Disclosure - Note Payable (Details Textual) Sheet http://www.entremed.com/role/NotePayableDetailsTextual Note Payable (Details Textual) Details http://www.entremed.com/role/NotePayable 19 false false R20.htm 120 - Disclosure - Fair Value Measurements (Details) Sheet http://www.entremed.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.entremed.com/role/FairValueMeasurementsTables 20 false false R21.htm 121 - Disclosure - Fair Value Measurements (Details 1) Sheet http://www.entremed.com/role/FairValueMeasurementsDetails1 Fair Value Measurements (Details 1) Details http://www.entremed.com/role/FairValueMeasurementsTables 21 false false R22.htm 122 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.entremed.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.entremed.com/role/StockholdersEquity 22 false false R23.htm 123 - Disclosure - Share-Based Compensation (Details) Sheet http://www.entremed.com/role/SharebasedCompensationDetails Share-Based Compensation (Details) Details http://www.entremed.com/role/SharebasedCompensationTables 23 false false R24.htm 124 - Disclosure - Share-Based Compensation (Details 1) Sheet http://www.entremed.com/role/SharebasedCompensationDetails1 Share-Based Compensation (Details 1) Details http://www.entremed.com/role/SharebasedCompensationTables 24 false false R25.htm 125 - Disclosure - Share-Based Compensation (Details 2) Sheet http://www.entremed.com/role/SharebasedCompensationDetails2 Share-Based Compensation (Details 2) Details http://www.entremed.com/role/SharebasedCompensationTables 25 false false R26.htm 126 - Disclosure - Share-Based Compensation (Details Textual) Sheet http://www.entremed.com/role/SharebasedCompensationDetailsTextual Share-Based Compensation (Details Textual) Details http://www.entremed.com/role/SharebasedCompensationTables 26 false false R27.htm 127 - Disclosure - Income Taxes (Details Textual) Sheet http://www.entremed.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://www.entremed.com/role/IncomeTaxes 27 false false R28.htm 128 - Disclosure - Related Party Transactions (Details Textual) Sheet http://www.entremed.com/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) Details http://www.entremed.com/role/RelatedPartyTransactions 28 false false All Reports Book All Reports casi-20160930.xml casi-20160930.xsd casi-20160930_cal.xml casi-20160930_def.xml casi-20160930_lab.xml casi-20160930_pre.xml true true ZIP 46 0001144204-16-133783-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-16-133783-xbrl.zip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

S\WOA/]0VG:132^ M$_VE1Y#Q?SKQGZ&C^-,[W^T_J.KJ/6Y;NFL_&:YFVG3Q[\AW[Z-I:[__\J__ M\J__(@@_K3W,"8%0!EQ9T6ZGFST:!&U5#S[B] W^AX2]L\79-T6D M?Y$A@[,J8)%JW^31^+)+ZF]$_$[FC%AM(+QL)#:/SWV10_6$IQ;X:1-6_$8 M14-ALEF#V66P9>UYWH9<2$!9\&DC@KZ0T'N&S?%PB".ZFB+YRXG;5-4:LQ) MZSJD=FUG6G-.V#H2;-TA-1*27(\R,=DB=9NCI=81J.M$U8F$%RD2NA:IK6J, MT3%-UR*U8YJN16K'-%V+U,XP[0S3KOE6AW_7?.P8$>PXO./P;H4[_#L./UX$ M.P[O.+Q];E?+RNRZ%JE'5&S4BM86K:DFZGI'=FS>L7G'YAV;=VS>^N+/CMT[ M=N_8O2VUSOLH]HO&[_)RN[S<[JRS1C75LBR'7!)LG9<;5BEP>3%2,BUWF^:A MK:-/E_W02807*1&ZM-Q6'<9T3-.EY79,TZ7E=DS3I>5VAFEGF'8)'QW^7<++ M,2+8<7C'X=T*=_AW''Z\"'8CR@5>J (_VY8&;ZEX MND]-TN^S2NWJZQM>;HE)C@GW\#R-+ M\/)XU.9L^Y;9)5FW::[U@7_-&KD-Z#5I77:FXPMAU):$^6O,KJ@S?L M"2[Q/)/>=M>J*\XK(W^< JL-IUD;2Z[#X)R-1?MOZ!7SYL^8[[%G&(7/1CNZHXZ"):P=O4-*&S?*Z3T*J'F*D#TINB$OP1L93 M2_^$46N;7B![_GU%+[&O<.+Q[79%-,_QEU^HW/9='/:&F'C%/#K?SW>.:KEX M(&);[L=G_I?3[X:;.C"13P3?,MB$O]U^.A%THAG C2Y2]1=)4283,290(?!I M3"\LS5Z2._5[?,?J+D<[2EN/=ESC3_)>F&*$6Y"D@%72?$VRXE]$(!'^&+)P#AEP&JW*& .% 0VI1:2+S$4 #ZHKM&X_V> MO3I)[?-=H1CQ#U2'(NJ:,BUCKHRSH=2RIIDW8V5E_OSPONI1TB3C-N?HY0IZ MK"HQMUO$?= L[Q"N,@F95!- K!%W&V(6:,VFCYDKXUATXIB-8>F(_#C'ZJ,/=-D\:UJ$$"1##M)^KVV>Q4WB(> M:/LY<9Q@0'HK/7]A?'!\#[J:J@:5GLM'Y_:N!U\LZ9D_N[1ZC5@E=\HWZYSK6R$F>@QRL'%4WUO8#G5/ M^3&8S_J,#R]M'58#WW%)C)=;PNU'ZK87.9III_36@R\7M@F(N.=_^$"NK[9' MZO%0AYV'VGFHG8>ZDX>:93-V'NI&)!1X&TOB C?A.P([+[51&Y MQ0@T2Y2^]ATPQ$&YGSXXA'EAZ\CY)4M\*(1+.;@+0+ A L.NJN!\<:<<315 M!/"MP<:,;5M9S(I,4,>"O@76H(L"05B%+*-&+ ,JP5L(H?=D6 ">YZ,)"GX> MNENJIL$@AD<'>@0GS ;C_ W.$\H56?QP$?X2?2=]>,L,^GI#(_(H+S82!"6L MAP%N#-=784)F,B?039*(?D\=2!>,AM#$CK!!@JO"RC$>P<\45J:J,2=7A:\? MX-4'_!H\ASHQQ,4AZF$E!M QB"JA'4W+,PP=B1=X5Q6 #@?XJKJZ^@<8CBO# S;\HCJ_ M@Y^58'EI&K(\95)8.GRR[K48]B1%ZHVGXR3BX!,Z*F4FAP1%+]0GJYL1$K/^ M$$X+)'LDCOH 9*=[5XVW=43M6E=>'$CR:'WIG\"^(!%0E!%8!".9KC4R_ 6L./"P),Z!PDE&"[N5I:+4C/'CO,X-H0I(!GC(O)]93@AB"P* M,7?L)65)C'S2/PJ0ZV*=+4(%&=&>SPF->*)$PH 0Y3=7]0QWSD['<:^$N@_D MN6^J(/>?*3=H,"% #I]">:;9ELZB,\'."T/H*\?60(^X@NO?_Y-H5/&LU.

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